Delivery of compounds and compositions to cells by disruption and fields

A microfluidic system with mechanical deformation and energy field perturbation addresses inefficiencies in intracellular delivery by enhancing payload transport to subcellular structures with improved efficiency and viability.

JP7591265B2Active Publication Date: 2024-11-28MASSACHUSETTS INST OF TECH
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021031352
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-10-08
Filing Date
2021-03-01
Publication Date
2024-11-28
Estimated Expiration
2035-11-13

AI Technical Summary

Technical Problem

Current methods for delivering compounds and compositions, such as DNA and RNA, into cells face challenges due to inefficient intracellular transport and potential cell damage from high electric fields, particularly in difficult-to-transfect cells, with unclear mechanisms and complex transport processes.

Method used

A microfluidic system with a cell-deforming constriction and an energy field, such as electric, magnetic, or acoustic, is used to temporarily perturb the cell membrane, allowing efficient delivery of payloads like DNA, RNA, and proteins to subcellular structures by combining mechanical deformation with field exposure.

Benefits of technology

This method enhances delivery efficiency and activity of payloads, such as gene expression, with higher cell viability compared to electroporation, enabling rapid and targeted delivery to organelles like the nucleus and mitochondria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591265000002
    Figure 0007591265000002
  • Figure 0007591265000003
    Figure 0007591265000003
  • Figure 0007591265000004
    Figure 0007591265000004
Patent Text Reader

Abstract

To provide microfluidic systems for delivering a payload, for example, polymers such as DNA, RNA, proteins, peptides, sugar polymers, and nanomaterials, and small molecules, to a cell, such as an eukaryotic or prokaryotic cell, through a cell membrane.SOLUTION: There is provided a microfluidic system for causing perturbations in a cell membrane, the microfluidic system comprising: a microfluidic channel defining a lumen and being configured such that a cell suspended in a buffer can pass through the lumen, the microfluidic channel having a cell-deforming constriction, and the diameter of the constriction being a function of the diameter of the cell; and (a) an energy field or (b) a source or emitter of an energy field positioned downstream, upstream, or upstream and downstream of the constriction.SELECTED DRAWING: Figure 9A-9C
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62,239,241, filed October 8, 2015, and U.S. Provisional Application No. 62 / 080,201, filed November 14, 2014, each of which is incorporated by reference in its entirety.

[0002] STATEMENT REGARDING FEDERALLY FUNDED RESEARCH This invention was made with Government support under Grant No. R01GM101420-01A1 awarded by the National Institutes of Health. The Government has certain rights in this invention.

[0003] The subject matter described herein relates to intracellular delivery of a compound or composition. [Background technology]

[0004] Many pharmaceuticals are primarily focused on developing small molecule drugs. These drugs are so named because of their relatively small size that allows them to diffuse freely throughout the body to reach their targets. These molecules can slip through normally impermeable cell membranes with little inhibition. However, for next-generation protein, DNA or RNA based therapeutics, the cells must be modified to facilitate delivery, as these molecules cannot easily pass through cell membranes. The established method is to breach the membrane using chemical or physical means to deliver the substance into the cytoplasm. Proper delivery into cells is a critical step in next-generation therapeutic research, development and implementation.

[0005] In the electroporation process for delivering substances into cells, DNA molecules accumulate during an electric pulse and interact with the electroporated plasma membrane. These DNA aggregates are then internalized into the cytoplasm and subsequently trigger gene expression (Golzio, M. et al., Proc. Natl. Acad. Sci. 99, 1292-1297 (2002); Paganin-Gioanni, A. et al. Proc. Natl. Acad. Sci. USA 108, 10443-7 (2011); Rosazza, C. et al., Mol. Ther. 21, 2217-2226 (2013); Boukany, P. E. et al. Nat. Nanotechnol. 6, 747-54 (2011); Teissie, J. et al., Biochim. Biophys. Acta 1724, 270-80 (2005); Yarmush, M. Lett. al., Annu. Rev. Biomed. Eng. 16, 295-320 (2014); Geng, T. & Lu, C., Lab Chip 13, 3803-21 (2013)). It is unlikely that DNA plasmids can penetrate the viscous and dense cytoplasm to reach the nucleus simply by diffusion (Lechardeur, D. et al., Adv. Drug Deliv. Rev. 57, 755-767 (2005); Dowty, ME et al., Proc. Natl. Acad. Sci. USA 92, 4572-4576 (1995)). Several studies have shown that DNA transport from the plasma membrane to the nucleus is an active biological process mediated by transport through the cytoskeleton, such as microtubule and actin networks (Rosazza, C. et al., Mol. Ther. 21, 2217-2226 (2013)). It has been found that microtubule and actin networks play an important role in DNA transport within the cytoplasm, and the time scale of such a process can be long depending on the cell type. The unclear mechanism and complex nature of DNA transport between the plasma membrane and the nucleus poses challenges in improving the performance of electroporation for difficult-to-transfect cells. Moreover, the strong electric fields used in current electroporation techniques can cause significant damage or death (Yarmush, M Let al., Annu. Rev. Biomed. Eng. 16, 295-320 (2014); Geng, T. & Lu, C., Lab Chip 13, 3803-21 (2013)). Technologies capable of delivering payloads directly into cells and organelles are needed. Summary of the Invention

[0006] The present invention provides solutions to problems and drawbacks associated with conventional methods of delivering compounds and / or mixtures of compounds to intracellular organelles such as the cytosol and cell nucleus. Aspects of the present invention provide a microfluidic system for inducing perturbations in a cell membrane, the system comprising a microfluidic channel defining a lumen and configured to allow cells suspended in a buffer to pass through the lumen. The system and method are useful for delivering cargo such as DNA, RNA, macromolecules such as proteins, peptides, sugar polymers, nanomaterials, and small molecules through the cell membrane to cells, e.g., eukaryotic or prokaryotic cells. The microfluidic channel has a constriction for cell deformation. The diameter of the constriction may be a function of the diameter of the cell, but does not exceed the diameter of the cell. Downstream of the constriction, the microfluidic channel comprises a source or emitter of an energy field. In various embodiments, the microfluidic system comprises an electrode(s) for generating an electric field, a magnet or electromagnet for generating a magnetic field, an acoustic source for generating an acoustic field, and / or a light source. In some embodiments, the energy source comprises an interdigitated electrode. The combination of cell deformation constriction and subsequent exposure to an energy field as described above for cells provides a synergistic effect in delivering cargo molecules into cells and / or transporting cargo molecules inside cells to subcellular structures such as the nucleus or mitochondria. Exposing cells to at least two different forces, e.g., a physical contraction force and an electrical force, results in a surprising improvement in the efficiency of delivery and in the activity of the delivered cargo, e.g., the expression of a protein encoded by the delivered nucleic acid.

[0007] In some embodiments, at least one electrode, magnet, acoustic device, or light source is adjacent to the cell deformation constriction, for example in a series arrangement, to generate a field.For example, one or more electrodes, magnets, acoustic devices, or light sources are located upstream, downstream, relative to the location of the constriction, to simultaneously deliver electric, magnetic, or acoustic signals to cells.For example, after the event of cell deformation constriction, expose the cell to an electric field, a magnetic field, an acoustic field, or an optical field.

[0008] In certain embodiments, the field or field emitter / source and the microfluidic channel are part of a single device of the system. Alternatively, the microfluidic system may have a first device and a second device, where the microfluidic channel is part of the first device and the emitter / source is inside the second device of the system. Field exposure occurs when the cells are inside the first device or outside the original (first) device. In some embodiments, the microfluidic system may have a first device and a second device, where the microfluidic channel is part of one device (first device) and the source / emitter is inside another device (second, third, or further device), whereby the energy field passes through the device with the microfluidic channel and emits from the device with the source / emitter.

[0009] In certain embodiments, the magnet (such as an electromagnet), acoustic device, or light source / emitter, and the microfluidic channel are part of a single device of the system. For example, the magnet or acoustic device may be downstream of a cell deformation constriction in the microfluidic channel. In other embodiments, where the microfluidic system has a first device and a second device, the microfluidic channel is part of the first device and the magnet, acoustic device, or light source / emitter is in the second device of the system. Field exposure occurs when the cells are inside the first device or outside the original (first) device. In some embodiments, the microfluidic system may have a first device and a second device, where the microfluidic channel is part of one device (the first device) and the light source / emitter is downstream of a cell deformation constriction in the microfluidic channel. The emitter's magnet, acoustic device is inside another device (second, third, or further device), thereby causing the energy field to pass through the device with the microfluidic channels and emanate from the device with the electrode(s).

[0010] In certain embodiments, the electrodes, or the electrodes and the microfluidic channels, are part of a single device of the system. Alternatively, the microfluidic system may have a first device and a second device, where the microfluidic channels are part of the first device and the electrode(s) are inside the second device of the system. Field exposure occurs when the cells are inside the first device or outside the original (first) device of the system. In some embodiments, the microfluidic system may have a first device and a second device, where the microfluidic channels are part of one device (the first device) and the electrode(s) are inside another device (the second, third, or further device), thereby causing the electric field to emanate from the device with the electrode(s) through the device with the microfluidic channels.

[0011] In some embodiments in which the at least one electrode, magnet, acoustic device, or light and the microfluidic channel are part of a single device, the at least one electrode, magnet, acoustic device, or light may be located downstream of the cell deformation constriction.

[0012] In various implementations of the invention, the diameter of the constriction is selected to induce a temporary perturbation of the cell membrane large enough to allow the passage of a payload, and the cells pass through the constriction to reach the field (i.e., electric, magnetic, acoustic, or optical field) in a continuous flow. After passing through the constriction, the cells may contact or pass through a portion of the field that has sufficient strength to transport the payload through the temporary perturbation. In other embodiments, the cells enter and remain in a zone or chamber of the device downstream of the constriction after passing through the constriction. The cells in this zone or chamber are then contacted with the field.

[0013] Aspects of the invention also relate to methods for delivering compounds or compositions to cells, for example by providing cells in a payload-containing solution, passing the solution through a microfluidic channel having a cell-deforming constriction, passing the cells through the constriction, thereby applying pressure to the cells and causing a perturbation of the cell membrane large enough to allow the payload to pass through, passing or contacting the cells with an electric, magnetic, acoustic, or optical field to further transport the payload into the cell and / or to transfer the payload from a first site, e.g., the cell membrane, to another, i.e., second site, e.g., the nucleus or other organelles or structures (such as mitochondria) inside the cell. For example, the first site can be a cytosol site or a region at or near the cytosol / plasma membrane interface, and the second site can be a mitochondrial or nuclear site. In some embodiments, the cells are treated according to a chronological order, i.e., the cells are first disrupted (e.g., squeezed, deformed, or compressed) and then exposed to an applied energy field, e.g., an electric, magnetic, or acoustic field.

[0014] In some embodiments, a payload may be added to the cell-containing solution after cell disruption and before or while the cells contact or pass through a portion of a field (such as an electric, magnetic, or acoustic field), thereby transporting the payload further into the cell and / or transferring the payload from a first location within the cell, e.g., the cell membrane, to another, i.e., second location, e.g., the nucleus or other organelle or structure (such as mitochondria).

[0015] In certain embodiments relating to a polypeptide payload, the polypeptide may include a localization signal. In some embodiments, the polypeptide payload is a fusion protein that includes a localization signal. For example, the polypeptide may include an endoplasmic reticulum retention signal, a nuclear localization signal, a nucleolar localization signal, a mitochondrial targeting signal, or a peroxisomal targeting signal. Such signals are known in the art. Non-limiting examples include Kalderon et al., (1984) Cell 39(3 Pt2):499-509; Makkerh et al., (1996) Curr Biol. 6(8):1025-7; Dingwall et al., (1991) Trends in Biochemical Sciences 16(12):478-81; Scott et al., (2011) BMC Bioinformatics 12:317(7 pages); Omura T (1998) J Biochem. 123(6):1010-6; Rapaport D (2003) EMBO Rep. 4(10):948-52; and Brocard & Hartig (2006) Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1763(12):1565-1573, the contents of each of which are incorporated herein by reference.

[0016] In embodiments involving electric fields, the electric field may be generated with at least one electrode or set of two electrodes on either side of the microfluidic channel or zone / chamber. In embodiments involving magnetic fields, the magnetic field may be generated with at least one magnet. Non-limiting examples of magnets useful in various embodiments involving magnetic fields include temporary magnets, permanent magnets, and electromagnets. In embodiments involving sound fields, the sound field may be generated with at least one acoustic device. Non-limiting examples of acoustic devices include speakers. In embodiments involving optical fields, the optical field may be generated with any light emitting device or ambient light may be used. Non-limiting examples of light emitting devices include light emitting diodes (LEDs), lasers, incandescent bulbs, or other visible light electromagnetic radiation sources.

[0017] In various implementations of the present invention, cells are passed through a microfluidic channel in a first device, then removed from the first device and contacted with an electric field, a magnetic field, or an acoustic field in a second device. In other implementations, the microfluidic channel and the electric field, the magnetic field, and the acoustic field are in one device. For example, cells may pass through a field in a continuous flow through a constriction, and after passing through the constriction, the cells contact or pass through a portion of the field that is strong enough to transport the payload via a temporary perturbation. Alternatively, after passing through the constriction, the cells may flow and remain in a zone of the device, where the cells contact the field.

[0018] The microfluidic system may include a plurality of microfluidic channels, each of which defines a lumen and is configured to allow cells suspended in a buffer to pass through the lumen. Additionally, each microfluidic channel has one or more cell-deforming constrictions. In some embodiments, the diameter of the constriction is a function of the diameter of the cell. Thus, there may be many microfluidic channels within the microfluidic system of the present invention. For example, the microfluidic system may include a plurality of, for example, 2, 5, 10, 20, 40, 45, 50, 75, 100, 500, 1,000 or more microfluidic channels arranged in parallel.

[0019] A microfluidic system with multiple parallel microfluidic channels allows for high throughput delivery of payloads to cells. Many cells can pass through each parallel channel in sequence. The cells may be exposed to an electric, magnetic or acoustic field during or after passing through the microfluidic channels. Multiple cells pass through each microfluidic channel, allowing a large number of cells to be processed in a short period of time. It will be understood that references to "cells" herein may refer to more than one cell, depending on the context. In a preferred embodiment, an electric, magnetic or acoustic field is applied to the cell downstream of the cell deformation constriction. That is, the cell is passed through the constriction, thereby deforming / destabilizing the cell membrane and allowing the payload to enter the cell. Following that event, the cell is exposed to an electric, magnetic or acoustic field. The electric, magnetic or acoustic field mediates the translocation of the payload within the cell (e.g., the payload that has entered the cell's cytoplasm as a result of a previous contraction step) to a subcellular structure within the cell, such as the nucleus.

[0020] In a preferred embodiment of the invention, the diameter of the constriction is selected to induce a transient perturbation of the cell membrane large enough to allow the payload to pass through. It will be appreciated that the diameter of the constriction may be adjusted based on the cell type and payload used.

[0021] Several variations in the placement of electrodes, magnets or acoustic devices are envisioned. In a preferred embodiment, electrodes are placed at only one end of the cell deformation constriction. In other embodiments, electrodes are placed at both ends, for example at the cell inlet and outlet ends of the cell deformation constriction. The microfluidic system may include two or more electrodes that generate an electric field to transport or extrude nucleic acids into cells suspended in a buffer solution or into the nucleus of a cell. For example, the electric field destabilizes the membrane of the nucleus or other organelles, such as mitochondria, thereby facilitating the entry of cargo into subcellular structures.

[0022] In some embodiments, the strength of the electric field is lower than that required to electroporate a cell, e.g., to introduce a nucleic acid through the plasma membrane of a cell. For example, a lower strength electric field may be used in DFE to achieve a comparable level of delivery for a given payload to a particular cell type. Unlike electroporation, which requires a field of sufficient strength to disrupt the cell membrane and transport the material toward the cytosol, the present disclosure provides membrane disruption by mechanical deformation and leverages the transport force of the field to facilitate the transfer of the material to the cytosol and intracellular compartments. By eliminating the use of electrical energy as the sole source for cell membrane disruption and / or embedding the material into the plasma membrane by field transport force, DFE allows for the use of lower electric field strengths that can pass the material through the mechanically damaged membrane and deliver it directly to the cytosol and intracellular compartments. In the same and other embodiments, the combination of the constriction and the electric field increases the efficiency of nucleic acid delivery to the cell nucleus. In some embodiments, the electric field may increase the permeability of the membrane. For example, the electric field may increase the permeability of intracellular membranes that cannot be directly disrupted by mechanical components. Without being bound by theory, mechanical disruption of the outer membrane may expose the inner membrane to field effects since there is no undamaged outer membrane. In a preferred embodiment of the present invention, the viability of cells passing through the microfluidic system to receive a payload is higher than when the corresponding cells are treated with electroporation. For example, substantially or about 1-50%, 1-10%, or about 5, 10, 15, 20, 25, 30, 35, 40, 40, 50, 60, 70, or 80% or more of the cells passing through the microfluidic system are viable compared to a corresponding population of cells treated only with standard electroporation conditions.

[0023] The microfluidic system may include a plurality of electrode pairs, each of which may have a different size (FIG. 2). In a non-limiting example, the plurality of electrode pairs may be arranged in at least a first and a second electrode pair array of electrode pairs, and the first electrode pair array may be offset relative to the second electrode pair array. In some embodiments, the microfluidic system includes a plurality of electrodes arranged in at least a first and a second electrode array. The first electrode array may be offset relative to the second electrode array. It will be appreciated that there are various ways in which different arrays of electrodes or electrode pairs may be offset relative to one another (e.g., at various angles relative to the X, Y, and / or Z planes). For example, the first array may be offset in the horizontal, vertical, or diagonal plane relative to the second array by substantially or about 1°, 5°, 10°, 15°, 20°, 25°, 30°, 35°, 40°, 45°, 50°, 55°, 60°, 70°, 80°, 90°, 1-10°, 1-20°, 1-30°, 1-45°, or 1-90°.

[0024] Cells can be exposed to the electric field for many different exposure times. For example, in preferred embodiments, the exposure time is substantially or about 10-50 ms, 50-100 ms, or 10-100 ms. Aspects of the invention have a substantially constant electric field between two or more electrodes. In some embodiments, the electric field is a constant current or a direct pulsed current. Preferably, the electric field is pulsed. In some embodiments, the electric field is pulsed for about 50-200 μs. The strength of the electric field may also vary. In some embodiments, the strength of the electric field or pulse strength may be substantially or about 1-3 kV / cm or 0.1-0.5, 0.1-1, 0.1-1.5, 0.1-2, 0.1-2.5, or 0.1-3 kV / cm. In some embodiments, the strength of the electric field or pulse strength may be substantially or about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, or 2.5 kV / cm. The strength of the electric field may be in the range of 0.1-10 kV / cm, or in certain cases, more broad. For example, the strength of the electric field or pulse strength is substantially or about 0.1-20 kV / cm, or less than 1 kV / cm. In various embodiments, the strength of the electric field or pulse strength is substantially or about 10-20 kV / cm, or less than 1 kV / cm. In some embodiments of the invention, the electric field is pulsed for a duration of substantially or about 0.1, 0.1-2, or 0.1-2000 ms with a period of 1-20, 0.1-2000, or 1-200 ms. In some cases, the electric field strength or pulse strength may be lower than the strength required to electroporate cells. For example, the electric field strength or pulse strength may be substantially or about 50, 1-50, 50-99, or 1-99% lower than the strength required to electroporate cells.

[0025] In some embodiments, a direct current is used to generate the electric field. In other embodiments, an alternating current is used to generate the electric field. The alternating current may oscillate uniformly or may have an asymmetric oscillation such that a net direct current occurs for the electric field force. The asymmetric oscillation may be achieved, for example, by applying an alternating current with a non-zero bias.

[0026] In some implementations, the subject matter combines the advantages of viral vector-free delivery by rapid mechanical cell deformation that causes a temporary perturbation with the advantages of electric fields that aid in the highly efficient delivery of payloads, such as DNA, into cells via the perturbation. In some implementations, the subject matter utilizes strengths that are lower than some conventional electroporation techniques, but higher than some sensing applications that may sense, for example, cell resistance. Exemplary sensing approaches are described in U.S. Patent Publication No. 2009 / 0280518 (Adamo et al.), published Nov. 12, 2009. Thus, to obtain a given delivery efficiency, some embodiments use electroporation with lower electric field strengths. Nucleic acid delivery and expression may also be achieved more quickly. More rapid delivery and expression of nucleic acids provides a significant advantage in DNA expression compared to electroporation alone or cell squeezing without a field. There are also significant advantages to using DFE to deliver other charged payloads, such as RNA. For example, by using DFE technology, more RNA can be delivered to a given cell compared to electroporation or field-free cell squeezing.

[0027] Electric and magnetic fields are particularly useful for transporting charged payloads into cells and intracellular compartments (such as organelles). The payload may be modified to optionally increase its charge, resulting in improved delivery by DFE. In some embodiments, a low or uncharged payload is modified to improve its delivery using an electric or magnetic field. For example, a protein can be conjugated to a charged compound, preferably using a covalent bond. Conjugation may be, for example, at the N-terminus or C-terminus (e.g., via a peptide bond) or at an amino acid side chain (e.g., via a disulfide bond with cysteine ​​or a bond with selenocysteine). This approach may be applied to a variety of payloads disclosed herein, without being limited to proteins.

[0028] In some embodiments, the conjugation is via a disulfide bond or another bond that is easily cleaved intracellularly. Examples of charged compounds that may be conjugated to the payload include singly charged amino acids (i.e., amino acid monomers that have one charge) and / or multiply charged amino acid stretches. In some embodiments, the charged amino acid stretch comprises a mixture of different amino acids that have a positive charge. In other embodiments, the charged amino acid stretch comprises a mixture of different amino acids that have a positive charge. The stretch of charged amino acids may comprise a mixture of different amino acids with negative charges. Alternatively, the stretch of charged amino acids may comprise repeats of the same amino acid. The amino acids may be natural, non-natural, or a combination thereof. The length of the stretch may vary depending on the size of the payload to be modified and the desired charge to be added to the payload. In various embodiments, the stretch of amino acids comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or 1-50 amino acid residues.

[0029] Examples of positively charged natural amino acids include arginine, histidine, and lysine. Examples of negatively charged natural amino acids include aspartic acid and glutamic acid. Examples of unnatural amino acids include those with positive charges, such as the D stereoisomers of arginine, histidine, and lysine, and those with negative charges, such as the D stereoisomers of aspartic acid and glutamic acid. Thus, for example, the payload may be modified to have an increased positive charge using one or more or any combination of natural amino acids, such as arginine, histidine, and lysine, and / or unnatural amino acids, such as the D stereoisomers of arginine, histidine, and lysine. Alternatively, the payload may be modified to have an increased negative charge using one or more or any combination of natural amino acids, such as aspartic acid and glutamic acid, and / or unnatural amino acids, such as the D stereoisomers of aspartic acid and glutamic acid.

[0030] In some embodiments, the pH of the buffer or solution is adjusted to increase the charge of the payload. For example, the pH may be lower or higher than the isoelectric point (pH(I)) of the payload. The payload has a net positive charge at a pH below the payload's pH(I) and a net negative charge at a pH above the payload's pH(I).

[0031] Implementations of the invention may also provide one or more of the following features: Deforming the cells includes deforming the cells for substantially or about 1 μs to 10 ms, such as 10 μs, 50 μs, 100 μs, 500 μs, and 750 μs Incubation is performed for substantially or about 0.0001 seconds to 20 minutes, such as substantially or about 1 second, 30 seconds, 90 seconds, 270 seconds, and 900 seconds.

[0032] The pressure and speed at which the cells pass through the microfluidic channel may also be varied. In some embodiments, a pressure of substantially or about 10-35 psi is used to pass the solution containing the cells through the microfluidic channel. The speed may be adjusted for a variety of reasons, including improving the viability of the treated cells while maintaining high payload delivery. In preferred embodiments, the cells pass through the microfluidic channel at a speed of substantially or about 300 mm / s, 100-300 mm / s, 200-700 mm / s, 250-400 mm / s, 1-1000 mm / s, 1 m / s, 2 m / s, 3 m / s, 4 m / s, 5 m / s, 6 m / s, 7 m / s, 8 m / s, 9 m / s, 10 m / s, 0.01-5 m / s, 5-10 m / s, or 0.01-10 m / s. In some embodiments, the cells pass through the electric field at a speed of substantially or about 100, 170, 300, 100-300, 200-700, 250-400, 100-1000 mm / s, or 1-1000 mm / s. If the cells are a plurality of cells, substantially or about 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 90-95, or 80-100% of the cells are viable after passing through the constriction and the electric field.

[0033] In some embodiments, cells are contacted with the electric field at a speed of 0 m / s. For example, the electric field may pass through a zone, region, or reservoir of the device that allows cells to contact the electric field. This electric field is turned on for a certain period of time and then turned off. In such a case, cells do not pass through the electric field, but the exposure to the electric field is still temporary.

[0034] The size and duration of the transient perturbation in the cell membrane can be modified by adjusting various factors such as the diameter of the cell deformation constriction and the speed at which the cell passes through the constriction. The disclosure provided herein regarding the size and duration of the perturbation should not be construed as limiting. A non-limiting description of perturbation and recovery is provided in Sharei et al., (2014) Integr. Biol., 6, 470-475, the entire contents of which are incorporated herein by reference. In some embodiments, the cell membrane perturbation may be characterized by a maximum diameter of substantially or about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm. In various embodiments, the perturbation of the cell membrane having a maximum diameter of substantially about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm persists on the cell membrane for at least substantially or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 1-10 minutes, or more (11, 13, 15, 18, 20 minutes or more).

[0035] In some embodiments, the cells may be compressed primarily by the fluid flow. In some embodiments, the diameter is smaller than the diameter of the cell. For example, the diameter of the constriction may be substantially or about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 20-99% of the cell diameter. Non-limiting examples of the diameter of the constriction include substantially or about 4, 5, 6, 7, 8, 9, 10, 15, 20 4-10 μm, or 10-20 μm. Various lengths of the constriction are also contemplated. Non-limiting examples of the length of the constriction include substantially or about 10, 15, 20, 24, 30, 40, 50, 60, 10-40, 10-50, 10-60, or 10-40 μm.

[0036] Many cells are 5-20 μm in diameter, e.g., naive T cells are 7-8 μm in diameter. For example, constriction diameters for processing of single cells are 4.5, 5, 5.5, 6, or 6.5 μm. In another example, constriction size / diameters for processing of human eggs are 60 μm-80 μm, although larger or smaller constrictions are also envisioned (human eggs are approximately 100 μm in diameter). In yet another example, embryos (e.g., clusters of 2-3 cells) are processed using constriction diameters of 12 μm-17 μm. In non-limiting examples for naive T and B cells, the device comprises a constriction having a length of about 10, 15, 20, 25, 30, or 10-30 μm, a width of about 3, 3.5, 4, or 3-4 μm, a depth of 15, 20, 25, or 15-25 μm, and / or an angle of about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 5-15°. Examples of microfluidic devices useful for delivering payloads to immune cells are described in PCT International Patent Publication No. PCT / US2015 / 058489, filed October 30, 2015, entitled "Delivery of Biomolecules to Immune Cells," the entire contents of which are incorporated herein by reference.

[0037] The present device and method are useful for the development and production of vaccines using professional antigen-presenting cells such as dendritic cells. For example, a method for stimulating antigen presentation is performed by subjecting dendritic cells to a controlled injury, such as a temporary contraction or high shear pulse, and contacting the dendritic cells with a solution containing a target antigen. The present method produces highly activated antigen-presenting cells compared to previous stimulation methods. Vaccine production is performed by passing dendritic cells or other antigen-presenting cells through a device with a constriction (thereby subjecting the cells to a rapid elongation event) and then incubating the cells in a solution containing a payload, such as an antigen. After rapid transformation of the cells, the cells are immersed in a cell culture medium containing one or more antigens (or nucleic acids encoding one or more antigens), but the rapid transformation event / process is not affected. The cells may be contacted with an antigen before, during, and / or after the process. In some embodiments, DFE is used to deliver nucleic acid, such as mRNA or DNA, that encodes an antigen or other gene product, thereby producing the gene product in the cell. DFE may also be used to deliver DNA to cells for the generation of CAR-T cells.

[0038] For example, constructs encoding chimeric antigen receptors (CARs) may be delivered to T cells using DFEs. In some embodiments, a CAR is a fusion of an extracellular recognition domain (e.g., an antigen-binding domain), a transmembrane domain, and one or more intracellular signaling domains.

[0039] In some embodiments, the compound is a nucleic acid encoding an MHC complex. In some embodiments, the compound is a nucleic acid encoding an MHC class I or MHC class II complex. In some embodiments, the nucleic acid encodes a chimeric antigen receptor, e.g., a chimeric T cell receptor. In some embodiments, the nucleic acid encodes a recombinant T cell receptor. For example, the nucleic acid encoding the chimeric antigen receptor is introduced into the T cell in a virus-free manner, i.e., by squeezing the cells, and the expression of the CAR-T is maintained. For example, the introduction of DNA is achieved without the use of viral particles. However, the nucleic acid construct, e.g., a plasmid, may contain viral genomic elements that may aid in integration or be maintained as an extrachromosomal nucleic acid.

[0040] In some embodiments involving delivery of DNA to a cell, the DNA may contain a construct with integration elements that facilitate insertion of the nucleic acid sequence into the genome of the cell.

[0041] Examples of nucleic acids include, but are not limited to, recombinant nucleic acids, DNA, recombinant DNA, cDNA, genomic DNA, RNA, siRNA, mRNA, saRNA, miRNA, lncRNA, tRNA, and shRNA. In some embodiments, the nucleic acid is homologous to a nucleic acid in the cell. In some embodiments, the nucleic acid is heterologous to a nucleic acid in the cell. In some embodiments, the nucleic acid is in the form of a plasmid. In some embodiments, the nucleic acid is a therapeutic nucleic acid. In some embodiments, the nucleic acid encodes a therapeutic polypeptide.

[0042] In some embodiments, the nucleic acid encodes a reporter or selection marker. Examples of reporter markers include, but are not limited to, green fluorescent protein (GFP), red fluorescent protein (RFP), aequorin, β-galactosidase, uroporphyrinogen III methyltransferase (UMT), and luciferase. Examples of selection markers include, but are not limited to, blasticidin, G418 / geneticin, hygromycin B, puromycin, zeocin, adenine phosphoribosyltransferase, and thymidine kinase.

[0043] Optionally use a surfactant (e.g., 0.1-10% by weight) in the running buffer (e.g., poloxamer, animal derived serum, albumin protein). Although the presence of a surfactant does not affect the delivery of molecules into cells, a surfactant is optionally used to reduce clogging of the device during operation.

[0044] In some embodiments, the device is fabricated from silicon, metal (e.g., stainless steel), plastic (e.g., polystyrene), ceramic, or any other material suitable for forming one or more appropriately sized channels or conduits. In some embodiments, the device is formed from a material suitable for etching micron-scale features and contains one or more channels or conduits through which cells pass. Silicon is particularly suitable, as is the case for micro-scale etching. This is because patterning methods are well established with this material, and therefore new devices can be easily manufactured, redesigned, etc. Furthermore, the rigidity of silicon can provide advantages, e.g., higher delivery rates, over more flexible substrates such as polydimethylsiloxane (PDMS). For example, the device can include 2, 10, 20, 25, 45, 50, 75, 100 or more channels. The device is microfabricated by etching silicon. Cells are moved (e.g., pushed) through the channels or conduits by applying pressure. The cell transport device can apply pressure. The cell transport device can include, for example, a pressurized pump, a gas cylinder, a compressor, a vacuum pump, a syringe, a syringe pump, a peristaltic pump, a manual syringe, a pipette, a piston, a capillary actor, and gravity. As an alternative to a channel, cells may be passed through a constriction in the form of a net or closely spaced plates. In either case, the width of the constriction through which the cells pass is 20-99% of the width or diameter of the cells to be treated when the cells are not contracted, i.e., in suspension. Temperature can affect the uptake and viability of the composition. The method is carried out at room temperature (e.g., 20° C.), physiological temperature (e.g., 39° C.), higher than physiological temperature, or lower (e.g., 0.1° C.), or at temperatures between these exemplary temperatures (0.1-40° C.).

[0045] In some embodiments, following controlled damage to the cells by contraction, stretching, and / or high shear rate pulses, the cells are incubated in a delivery solution containing the compound or molecule that one wishes to introduce into the cells. The cells may be contacted with the field when in a solution containing the compound or molecule. The controlled damage may be characterized as a small wound in the cell membrane, for example a 200 nm diameter wound. The recovery period for the cells to close the damage caused by passing through the constriction is on the order of a few minutes. The delivery period may be 1-10 minutes or more, for example 15, 20, 30, 60 minutes or more, with 2-5 minutes being optimal when operated at room temperature.

[0046] Various implementations of the present invention may provide one or more of the following capabilities: Delivery can be accomplished with greater accuracy and scalability compared to the prior art. Delivery of material to cells can be automated. Materials such as proteins, RNA, siRNA, peptides, DNA, and impermeable dyes can be implanted into cells such as embryonic or induced pluripotent stem cells (iPSCs), primary cells or immortalized cell lines. The present device and method are suitable for any cell type, and the size of the constriction is tailored to the cell type being treated. The present device and method can provide significant advantages. For example, experimental noise in current systems can be reduced compared to the prior art. The amount of material delivered can be consistent across a population of cells. Cells can be treated individually, rather than as a batch. The present invention also shows a significant unique potential for delivery of various nanoparticles and proteins to the cytosol. Existing methods are fairly unreliable and inefficient in performing such functions.

[0047] The method and device of the present invention delivers nucleic acids to cells and subcellular structures (e.g., nuclei and mitochondria) more quickly and efficiently than other methods. Electroporation results in DNA accumulation during the electric pulse and interaction with the electroporated plasma membrane, which causes DNA aggregates to be internalized into the cytoplasm and accumulate adjacent to the cell membrane within the cell (Figures 12 and 21). DNA cannot easily penetrate the viscous and complex cytoplasm to reach the nucleus simply by diffusion. Delivering nucleic acids to the cytosol and nucleus (as well as mitochondria) by DFE using an electric field is rapid and efficient while maintaining cell viability, thereby overcoming the long-standing shortcomings of electroporation alone.

[0048] Various implementations of the present invention may also provide one or more of the following features: DNA can be delivered to difficult to reach cells such as stem cells, primary cells, immune cells, etc. Delivery of very large plasmids (even entire chromosomes) can be achieved. Quantitative delivery of known amounts of gene constructs to cells can also be easily achieved to test their sensitivity to gene expression levels and concentrations. Known amounts of enzymes that enhance DNA recombination can be delivered along with known amounts of DNA sequences to achieve easier / more efficient and stable delivery, homologous recombination, and site-specific mutagenesis. The methods and devices described herein can also be useful for quantitative delivery of RNA for more efficient / conclusive RNA testing. Delivery of small interfering RNA (siRNA) to the cytoplasm of cells is also easily achieved.

[0049] Various implementations of the present invention may provide one or more of the following capabilities: RNA can be delivered to cells for RNA silencing without the need for liposomes; A known amount of RNA molecules can be delivered with a known amount of Dicer molecules to achieve standardized efficient RNA across multiple cell lines under different conditions; mRNA can be delivered into cells to test aspects of gene expression regulation at the post-transcriptional level; The method is also useful for delivering a fixed amount of RNA label to test RNA half-life, as well as using RNA-based interference such as miRNA and lncRNA against mitochondrial DNA; Universal protein delivery can be achieved; A known amount of labeled protein can be delivered to test half-life within cells; A labeled protein can be delivered to examine protein localization; A known amount of tagged protein can be delivered to test protein-protein interactions in the intracellular environment; A labeled antibody can be delivered into live cells for immunostaining and fluorescence-based Western blotting.

[0050] Various implementations of the present invention may also provide one or more of the following clinical and research capabilities: Quantitative delivery of drugs to cell models can be achieved for improved screening and dose studies. The method can be deployed as a high-throughput method to screen protein activity in the cytosol to identify protein therapeutics or aid in understanding disease mechanisms. Such applications are currently severely limited due to inefficiencies under current protein delivery methods. The present devices and techniques are useful for intracellular delivery of drugs to specific subsets of circulating blood cells (e.g., lymphocytes), high-throughput delivery of sugars to cells to improve cryopreservation of cells, particularly oocytes, targeted cell differentiation by introduction of proteins, mRNA, DNA, and / or growth factors, delivery of gene or protein agents to induce cell reprogramming to produce iPS cells, delivery of DNA and / or recombinant enzymes to embryonic stem cells for the generation of transgenic stem cell lines, delivery of DNA and / or recombinant enzymes to zygotes for transgenic generation, DC cell activation, iPSC generation, and stem cell differentiation, nanoparticle delivery for diagnostic and / or mechanistic testing, and introduction of quantum dots. Skin cells used in connection with plastic surgery may also be modified using the devices and methods described herein.

[0051] Methods and devices relating to the use of electric fields for DFE are particularly useful for the delivery of nucleic acids and other charged compounds. DFE is significantly more efficient at delivering charged substances than cell squeezing alone. See, e.g., Figures 12B and 12C.

[0052] In some embodiments of the devices and methods described herein, stem or progenitor cells, e.g., induced pluripotent stem cells (iPSCs), are passed through a constricted channel, which does not induce differentiation but does induce uptake of a composition into the cells. For example, a differentiation factor is introduced into such cells. After uptake of the introduced factor, the cells follow a differentiation pathway defined by the introduced factor without problems associated with the method of introduction of the factor(s) into the cells.

[0053] In addition to single cells, very large cells, e.g. egg cells with a diameter of approximately 200 μm, and cell clusters, e.g. clusters of 2–5 cells such as embryos containing 2–3 cells, can be processed and targeted. Introduce the target composition. Adjust the size of the opening accordingly, i.e., so that the width of the constriction is slightly smaller than the size of the cluster. For example, the width of the channel is 20-99% of the width of the cell cluster.

[0054] The cells or cell clusters are purified / isolated or enriched for the desired cell type. Dendritic cells or other cells used in the method may be purified or enriched, for example immune cells such as macrophages, B cells, T cells, or stem cells such as embryonic stem cells or iPS. For example, the cells are isolated or enriched by expression of a cell surface marker or other distinguishing characteristic. Dendritic cells are identified and isolated by expression of β-intergrin, CD11c, or other distinguishing cell surface marker. With respect to cells, the term "isolated" means that the cells are substantially free of other cell types or cellular material as they naturally occur. For example, a cell sample of a particular tissue type or phenotype is "substantially pure" if it is at least 60% of the cell population. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% or 100% of the cell population. Purity is measured by any suitable standard method, for example, fluorescence activated cell sorting (FACS).

[0055] Payload compositions such as polynucleotides, polypeptides, or other agents may be purified and / or isolated. Specifically, as used herein, an "isolated" or "purified" nucleic acid molecule, polynucleotide, polypeptide, or protein is substantially free of other intracellular material, or culture medium if produced by recombinant techniques, or chemical precursors or other chemicals if chemically synthesized. A purified compound is at least 60% by weight (dry weight) of the compound of interest. Preferably, the preparation is at least 75% by weight, more preferably at least 90% by weight, and most preferably at least 99% by weight of the compound of interest. For example, a purified compound is at least 90%, 91%, 92%, 93%, 94%, 95%, 98%, 99%, or 100% (w / w) of the desired compound. Purity is measured by any appropriate standard method, such as, for example, column chromatography, thin layer chromatography, or high performance liquid chromatography (HPLC) analysis. A purified or isolated polynucleotide (ribonucleic acid (RNA) or deoxyribonucleic acid (DNA)) is free of the genes or sequences that flank it in its naturally occurring state. Examples of isolated or purified nucleic acid molecules include: (a) DNA that is a portion of a naturally occurring genomic DNA molecule, but is not flanked by both nucleic acid sequences that flank that portion of the molecule in the genome of the organism in which it naturally occurs; (b) a nucleic acid that has been incorporated into a vector or prokaryotic or eukaryotic genomic DNA such that the resulting molecule is not identical to any naturally occurring vector or genomic DNA; (c) a separate molecule such as a cDNA, genomic fragment, a fragment generated by polymerase chain reaction (PCR), or a restriction enzyme cleavage fragment; (d) a recombinant nucleotide sequence that is part of a hybrid gene, i.e., a gene encoding a fusion protein. Isolated nucleic acid molecules according to the present invention further include synthetically produced molecules, as well as any chemically and / or backbone modified nucleic acid.

[0056] Some applications require purity, while in other applications delivery using the methods and devices of the present invention uses heterogeneous mixtures of compounds, in some embodiments high purity is not required for efficient delivery.

[0057] The suspending solution is either a physiological or cytocompatible (e.g., a buffer or solution in which the cells can survive or grow during the DFE) buffer or solution. For example, the suspending solution is cell culture medium or phosphate buffered saline. For example, one non-limiting example of a suitable buffer for HeLa cells is 25 mM KCl, 0.3 mM KH2PO4, 0.85 mM K2HPO4, 36 mM myo-inositol, pH 7.2, approximately 90 mOsm The buffer solution may have an osmolality of about 0.1-5 mS / cm, 0.1-4 mS / cm, e.g., about 3.5 mS / cm at 25°C. The buffer may be changed or modified while maintaining payload delivery performance. For example, myo-inositol may be substituted with glucose at the same concentration while still providing comparable performance. The buffer or solution may be adjusted based on many factors and considerations, such as the type and strength of the field used, the cell type, and the constriction used. The molar osmolality and conductivity may be adjusted, as well as the presence or absence of ions such as potassium and calcium. In certain embodiments, the solution or buffer has a conductivity of substantially or about 1 mS-10 mS or 0.5 mS-15 mS, and / or an osmolality of 1-310 or 10-300 mOsm / L. In some embodiments, the pH of the buffer is substantially or about 4-10, 5-9, 6-8, 6.5-7.5, or 7. In some embodiments, the buffer is a buffer suitable for electroporating the cell type being treated. Buffers suitable for electroporation may be used in embodiments regardless of whether the electric field strength is sufficient for electroporation.

[0058] When transporting a payload via perturbation by an electric field, the diameter of the constriction may be selected to induce a temporary perturbation of the cell membrane large enough for the payload to pass through. Non-limiting examples of payloads that may be delivered using the microfluidic system of the present invention include proteins (such as antibodies and fragments thereof); small molecules; carbohydrates; sugars; polymers of biological, synthetic, organic, or inorganic molecules; deoxyribonucleic acid (DNA); ribonucleic acid (RNA) (such as small interfering RNA, hairpin RNA, repeat sequence-associated small interfering RNA, microRNA, self-amplifying RNA, and mRNA molecules). DNA or RNA containing modified nucleotides that increase the stability or half-life of the DNA or RNA in vivo or in vitro; peptide nucleic acid (PNA); methylated DNA; naturally occurring chromosomes or portions thereof; and / or expression vectors such as plasmids. In some embodiments, the payload comprises a mixture of different compounds, such as one or more of proteins, small molecules, carbohydrates, sugars, polymers, DNA, RNA, modified or methylated DNA or RNA, PNA, naturally occurring chromosomes or portions thereof, and / or expression vectors such as plasmids. In some embodiments, the DNA molecule is single-stranded, double-stranded, circular, linear, or supercoiled. In embodiments involving double-stranded linear DNA, the DNA may have, for example, blunt ends or one or more 5' or 3' overhanging ends of nucleic acids. The small molecule may be, for example, an organic compound with a size of less than 1 kDa. In some embodiments, the payload is charged, and in other embodiments, the payload is uncharged. Without wishing to be bound by any scientific theory, the methods and systems provided herein may be used to deliver uncharged and charged molecules by electric field-induced fluid flow when salt interacts with the electric field.

[0059] In embodiments delivering a payload to a eukaryotic cell, the payload may be transported to the cytoplasm, organelles (such as mitochondria), and / or nucleus of the cell. For example, the payload is transported to the nucleus of the cell while the cell is passing through the electric field or less than substantially or about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, or 4 hours after the cell has passed through the electric field. In embodiments involving payload delivery to a plurality of cells, at least substantially or about 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 100, 0-65, or 10-100% of the plurality of cells express the DNA substantially or about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 0.1-4, or 0.1-48 hours after the plurality of cells has passed through the electric field.

[0060] In some embodiments, the cell is a prokaryotic cell. Non-limiting examples of prokaryotic cells include bacterial cells (e.g., gram-positive, gram-negative, pathogenic, non-pathogenic, symbiotic, cocci, bacilli, and / or spiral bacterial cells) and archaeal cells. In other embodiments, the cell is a eukaryotic cell. Non-limiting examples of eukaryotic cells include protozoa, algae, fungi, yeast, plants, animals. The cell may be, for example, a cell of a unicellular organism or a multicellular organism. The cell may be, for example, a prokaryotic cell or an immortalized eukaryotic cell. In some embodiments, the cell is a cancer cell. In certain embodiments, the cell is other than a human cell. In various embodiments, the cell may be a mixture of two or more cell types, or the plurality of cells may be a mixture of two or more cell types. The mixture of cell types may be a co-culture of multiple cell types (e.g., two or more of those disclosed herein) or may be a mixture of cell types that naturally exist together, such as those in whole blood.

[0061] In some embodiments, the cells are peripheral blood mononuclear cells. In various embodiments, the cell suspension comprises a purified cell population. In certain embodiments, the cells are primary cells or cells of a cell line.

[0062] In some embodiments, the cells are blood cells. In some embodiments, the blood cells are immune cells. In some embodiments, the immune cells are lymphocytes. In some embodiments, the immune cells are T cells, B cells, natural killer (NK) cells, dendritic cells (DCs), NKT cells, mast cells, monocytes, macrophages, basophils, eosinophils, or neutrophils. In some embodiments, the immune cells are adaptive immune cells, such as T cells and B cells. In some embodiments, the immune cells are innate immune cells. Examples of innate immune cells include innate lymphoid cells (ILC1, ILC2, or ILC3), basophils, eosinophils, mast cells, NK cells, neutrophils, and monocytes. In some embodiments, the immune cells are immune memory cells. In some embodiments, the immune cells are primary human T cells. In some embodiments, the cells are mouse, dog, cat, horse, rat, goat, monkey, or rabbit cells. In some embodiments, the cells are human cells. In some embodiments, the cell suspension contains non-mammalian cells. In some embodiments, the cells are chicken, frog, insect, or nematode cells. Aspects of the invention relating to cells also apply to platelets. Thus, references herein to "cells" can also apply to platelets.

[0063] In some embodiments, a microfluidic channel has a single cell-deforming constriction (i.e., not more than one), while in other embodiments, a microfluidic channel has a series of multiple cell-deforming constrictions.

[0064] In various embodiments, the cells may be deformed within substantially or about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, 0.0001-10, 0.0001-20, 0.0001-30 seconds or more (e.g., about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.1-10, 1-15, or 1-20 seconds) after exiting the cell deformation constriction. 15 minutes or more) or within about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, 0.0001-10, 0.0001-20, 0.0001-30 seconds, or within about 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.1-10, 1-15, or 1-15 minutes after the cell deforms and leaves the constriction. It will be appreciated that the distance between the electrode and the constriction can vary depending on factors such as the speed at which the cells are migrating.

[0065] In some embodiments, the cell deformation constriction event induces a transient perturbation of the cell membrane that is large enough to allow the payload to pass through. In some aspects, at least one electrode is proximate to the cell deformation constriction, thereby exposing the cell to an electric field while the cell membrane is transiently perturbed. Non-limiting examples of a distance "proximate" to the cell deformation constriction include a distance of substantially or about 0.5 mm. .1, 0.5, 1, 2, 3, 4, 5, 0.1-5cm, 1-10, 1-100, or 1-1000cm.

[0066] Any of the above methods are performed in vitro, ex vivo, or in vivo. For in vivo applications, the device may be implanted into a blood vessel lumen, for example, an in-line stent. These and other capabilities of the present invention will be more fully understood after consideration of the following drawings, detailed description, and claims, as well as the invention itself.

[0067] Aspects of the invention provide methods for delivering an expression vector encoding a transgene to a cell. In a preferred embodiment, the method comprises passing a solution containing the cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells to cause a perturbation of the cell membrane large enough to allow the expression vector to pass through. Before, during, and / or after exiting the cell deformation constriction, the cells may be contacted with an electric, magnetic, or acoustic field.

[0068] In some embodiments, the transgene is expressed in the cells sooner than a corresponding cell contacted with an electric, magnetic or acoustic field without passing through a cell deformation constriction, for example, the transgene may be expressed 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1-4 hours sooner than a corresponding cell contacted with an electric, magnetic or acoustic field without passing through a cell deformation constriction.

[0069] In various embodiments, maximum expression of the transgene in the cells is achieved at a faster rate than maximum expression of the transgene in the corresponding cells contacted with an electric field, magnetic field, or acoustic field without passing through a cell deformation constriction. For example, maximum expression of the transgene in the cells may be achieved 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours earlier than maximum expression of the transgene in the corresponding cells contacted with an electric field, magnetic field, or acoustic field without passing through a cell deformation constriction.

[0070] In certain embodiments, the transgene is more extensively expressed in the cells compared to the expression of the transgene in a corresponding cell that is contacted with an electric field, a magnetic field, or an acoustic field without passing through a cell deformation constriction. For example, the expression of the transgene in the cells may be at least substantially or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% higher, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold, or more higher than the expression of the transgene in a corresponding cell that is contacted with an electric field, a magnetic field, or an acoustic field without passing through a cell deformation constriction.

[0071] Aspects of the invention also relate to methods of delivering an expression vector encoding a transgene to a cell population. In a preferred embodiment, the method comprises passing a solution containing cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells and causing a perturbation of the cell membrane large enough to allow the expression vector to pass through. Before, during, and / or after exiting the cell deformation constriction, the cells may be contacted with an electric, magnetic, or acoustic field.

[0072] In some embodiments, the percentage of cells expressing the transgene in the population is greater than the percentage of cells expressing the transgene in a corresponding cell population contacted with an electric, magnetic, or acoustic field without passing through a cell deformation constriction. For example, the percentage of cells expressing the transgene in the population may be at least substantially or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold, or more greater than the percentage of cells expressing the transgene in a corresponding cell population contacted with an electric, magnetic, or acoustic field without passing through a cell deformation constriction.

[0073] In some embodiments, expression of the transgene in the cells may be at least substantially or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater within substantially or about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1-4 hours after the cells have passed through the cell deformation constriction, compared to expression of the transgene in a corresponding cell that has been contacted with an electric, magnetic, or acoustic field without passing through the cell deformation constriction.

[0074] In certain embodiments, the percentage of cells expressing a high level of the transgene in a population is greater than the percentage of cells expressing a high level of the transgene in a corresponding cell population contacted with an electric field, magnetic field, or acoustic field without passing through a cell deformation constriction. For example, the percentage of cells expressing a high level of the transgene in a population may be at least substantially or about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold, or more greater than the percentage of cells expressing a high level of the transgene in the same cell population when contacted with an electric field, magnetic field, or acoustic field without passing through a cell deformation constriction. In some embodiments, a "high level" of transgene expression refers to a level of expression in a cell that is 50% greater than the average level of transgene expression in the same cell when contacted with an electric field, magnetic field, or acoustic field without passing through a cell deformation constriction. Non-limiting examples of methods for measuring the level of transgene expression include quantitative polymerase chain reaction (qPCR) assays, Northern blots, Western blots, and microarray-based assays.

[0075] Each embodiment disclosed herein is believed to be applicable to each of the other embodiments disclosed, and thus, all combinations of the various elements described herein are within the scope of the invention.

[0076] Related devices, systems, techniques, and articles are also described.

[0077] The details of one or more variations of the subject matter described herein are set forth in the accompanying drawings and the description below. Other features and advantages of the subject matter described herein will become apparent from the description and drawings, and from the claims. [Brief description of the drawings]

[0078] [Figure 1]FIG. 1 is a diagram of an exemplary implementation of a microfluidic device for delivering a payload, such as DNA or RNA, to cells for genetic modification. [Diagram 2] 2 is an alternative implementation of the electrodes shown in FIG 1. The offset in the electrodes facilitates exposing cells to the electric field as they flow in, independent of their position in the channel. [Diagram 3] 1 is a bar graph showing DNA transfection rates of exemplary cells transported through a microfluidic system to deliver payload DNA. DFE10-6 indicates the dimensions of the constriction of the DFE device, with the first number corresponding to the length of the constriction and the second number corresponding to the width (in microns). [Figure 4] 1 is a bar graph showing cell viability. [Diagram 5] 1 is a line graph showing DNA transfection rate and survival rate. [Figure 6] 1 is a bar graph showing how exposure time to such buffers prior to treatment affects DNA delivery and cell viability. [Figure 7] 1 is a line graph illustrating that increasing cell velocity also increases cell viability. [Figure 8A] FIG. 1 is a schematic diagram of an embodiment of a microfluidic system illustrating a single constriction channel. [Figure 8B] FIG. 1 is an illustration of a single constriction channel of a microfluidic system, showing its depth, width, and length. [Figure 9] Figures 9A-C show the device structure and mechanism of action. (Figure 9A) Schematic of the mechanism of action. Mechanical disruption of the cell as it passes through the constriction creates a hole in the cell membrane. An electric pulse then transports the DNA through this hole into the cytoplasm and nucleus. (Figure 9B) A set of identical parallel microfluidic constrictions is etched on a silicon wafer and a set of electrodes is evaporated onto a Pyrex wafer. (Figure 9C) Optical image of the completed device bonded by the silicon wafer and Pyrex layer. Further details regarding the fabrication of the device can be found in Figure 13. [Figure 10]Figures 10A and 10B are bar graphs showing the transfection performance depending on the electric pulse. The DNA transfection efficiency (Figure 10A) and cell viability (Figure 10B) after 24 hours of treatment are shown as a function of the amplitude of the applied electricity. By introducing mechanical disruption before performing the electric transfection, the DNA transfection rate is significantly improved with little effect on the cell viability. The DNA transfection efficiency and cell viability of the GFP plasmid were measured by flow cytometry after propidium iodide staining. As shown in Figure 10A, at each electric field strength, a greater DNA expression was achieved compared to electrophoresis, indicating that the energy level required for electric field DFE is lower than that of electrophoresis. Data were collected in triplicate for all data points, and the error bars represent 2SD. The unit of the x-axis is Volts / 60um. 1V / 60um is approximately equivalent to 0.1667kV / cm. [Figure 11]11A-11C are graphs showing the results of a comparative study on the efficiency of transfection of plasmid DNA into HeLa cells using different methods. (FIG. 11A) The expression efficiency of GFP is shown as a function of time after treatment. Efficiency is defined as the number of GFP-expressing cells relative to the total number of live cells after treatment. A 10-7 tip is used for squeezing and for disruption and delivery by field (DFE). As used herein, the dimensions of the device are indicated by a series of numbers indicating the length and width (e.g., 10-7 indicates a device with a single constriction of 10 μm in length and 7 μm in width). A pulse of 0.1 ms / 10v with a frequency of 200 Hz is used for EP and ME (microfluidics (no constriction) + electric field), and a single pulse of 15 ms / 15000v is used in BEP. (FIG. 11B) The dynamics of DNA expression is analyzed by measuring the differential expression fluctuation of GFP at different time points after treatment. More than 80% of transfected cells expressed GFP within 1 hour after microinjection and treatment with DFE. In contrast, the majority of transfected cells express GFP 4-48 hours after treatment in ME (60%), BEP (70%), and LP2000 (95%). The number of HeLa cells in each run for each method is also shown, which represents the throughput of each technique (Figure 11C). Each data point was run in triplicate, and error bars represent 2SD. [Figure 12]Figures 12A-C are photographs showing the visualization of the delivery of fluorescently labeled plasmid DNA (LDNA) into HeLa cells. After nuclear and plasma membrane staining, cells were mixed with Cy3-labeled plasmid DNA before transfection. After treatment, cells were washed with OPTI MEM and fixed with a cell fixation kit for confocal imaging analysis. (Figure 12A) In BEP, a 0.1 ms (200 Hz) electric pulse of 10 V was applied as the cells passed through the tip at a speed of 500 mm / s (as the cells passed the constriction). DNA accumulation was observed on the plasma membrane. (Figure 12B) When cell squeezing alone was used, little or no LDNA signal was observed in the cells. A 10-7 tip was used with a cell speed of 500 mm / s. (Figure 12C) In DFE, significant Cy3 fluorescence was observed filling the cytoplasm and nucleus. A 10-7 tip was used, applying electrical pulses of 0.1 ms (200 Hz) at 10 V with a cell speed of 500 mm / s. [Figure 13] Diagrams of an exemplary device fabrication process. (Fig. 13a-d) Fabrication of electrodes on the Pyrex layer includes a metal evaporation process followed by a lift-off process. (Fig. 13e-h) Fabrication of microchannels on silicon wafer using two lithography and DRIE processes. (i) Bonding between silicon substrate and Pyrex layer. [Figure 14] Figure 1 is a line graph showing the delivery performance depending on the cell velocity. After 24 hours of treatment, the delivery efficiency of 3K Da dextran, DNA transfection efficiency, and cell viability were measured. A 10-8 chip was used, and the electric pulse was 10 V at 0.1 ms (200 Hz). The DNA transfection efficiency was maximum at a cell velocity of around 300 mm / s. [Figure 15] Figures 15A and B show fluorescence images of HeLa cells. (Figure 15A) Comparison of GFP plasmid DNA expression by DFE, BEP, and LP2000. Fluorescence microscopy images of cells show that GFP expression occurred much faster in DFE than in BEP and LP2000. (Figure 15B) Comparison of DFE and BEP including the 8 hour time point. [Figure 16]Histograms showing the GFP fluorescence intensity distribution at different times after treatment with DFE and NEON (BEP). The GFP fluorescence intensity distribution of HeLa cells is shown in a histogram measured by flow cytometry at different times after treatment. The results indicate that DNA transcription occurs immediately after delivery with DFE, whereas intracellular transport of DNA with BEP requires several hours. Cells begin to express GFP immediately after DFE treatment, whereas electroporation requires more than 4 hours to transcribe DNA after treatment. The mean fluorescence intensity also appears to be superior for DFE compared to BEP. The histogram of expressing cells is shifted to the right for DFE compared to NEON, indicating higher protein expression even at 24 hours. [Figure 17] GFP DNA expression in mESCs after 24 hours. Fluorescent microscopy images show GFP expression in mouse embryonic stem cells (mESCs) 24 hours after DFE delivery of GFP DNA plasmid. [Figure 18] 1 is a line graph showing the simultaneous delivery of DNA, mRNA and protein (IgG2) to cells. The figure shows the delivery efficiency of each substance at different amplitudes during simultaneous delivery. The y-axis is % expression / delivery. This is % expression for mRNA and DNA, and % delivery for IgG2. [Figure 19] 1 illustrates an exemplary apparatus of the present invention. [Figure 20] FIG. 13 provides non-limiting examples of device parameters. [Figure 21] Figures 21A-C show the distribution of DNA delivered (A) using electroporation, (B) using cell squeezing alone, and (C) using DFE. See also Figures 12A-C. As shown in Figure 12A and depicted in Figure 21A, DNA delivered by electroporation accumulates on the plasma membrane. Figure 12B (shown in Figure 21B) shows that cell squeezing alone results in little or no DNA delivery. However, Figure 12C (shown in Figure 22C) shows that using DFE rapidly and dramatically increases DNA delivery throughout the cell.

[0079] Like reference symbols in the various drawings indicate like elements. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0080] Intracellular delivery of macromolecules such as DNA and RNA is a key step in many therapeutic and research applications. Gene delivery can be achieved by viral-mediated, chemical, electrical and mechanical transfection. Methods based on viral vectors, while effective for certain applications, often carry the risk of chromosomal integration, posing safety risks for in vivo use. Chemical modification of target molecules can also facilitate membrane pore generation or endocytotic delivery, but these approaches are often limited by the structure of the target molecule and the target cell type. Microinjection has the disadvantage of low throughput. Electroporation has demonstrated its effectiveness in DNA and RNA delivery applications in cells that have been previously difficult to transfect. However, this method can cause cell death and damage sensitive materials such as quantum dots due to the high strength of the electric field. The constriction microfluidic platform can produce temporary cell membrane disruption that facilitates passive diffusion of most materials into the cytoplasm of almost all cell types. This delivery platform is a promising candidate for a wide variety of applications. This platform has the advantages of high throughput, independence from exogenous substances or fields, and high cell viability.An example of a delivery platform based on membrane disruption is described in US Patent Publication No. 2014 / 0287509, published on September 25, 2014, the entire contents of which are expressly incorporated herein by reference.However, when combined with an electric field, it is possible to induce gene expression in response to the delivery of plasmid DNA.The subject matter encompasses intracellular delivery techniques and platforms that can deliver any functional target molecule to any cell type.

[0081] The present subject matter includes a high-throughput, vector-free microfluidic device for delivering DNA into cells using transient mechanical cell membrane disruption and electric fields.

[0082] FIG. 1 is a diagram of an implementation of a microfluidic device 100 for delivering a payload, such as DNA or RNA, to cells for genetic modification. The microfluidic device 100 comprises one or more constriction channels 105 and at least one electrode 110 for generating an electric field. The at least one electrode 110 can include electrode pairs of different sizes. The constriction channel 105 is shown on the left and is dimensioned to constrict the cell as it passes through the channel 105 at a constriction point 107. When the cell passes through the constriction point 107, which has a minimum dimension smaller than the cell diameter, the cell undergoes rapid mechanical deformation, forming a temporary membrane rupture hole.

[0083] Molecules from the surrounding medium can then diffuse through these holes into the cytosol of the cell. After passing through the constriction point 107, the cell enters the electric field generated by the electrode 110 located downstream of the constriction point 107, where the payload, such as DNA, is transported into the cell by the electrophoretic effect caused by the electric field. If the payload is in a charged state, it can be transported directly, if the payload is uncharged, it can be transported indirectly, for example, by suspending the payload in a buffer containing a charged component, such as a salt, which acts to transport the payload under the electrophoretic effect generated by the electric field. The electrode 110 is shown on the right side of FIG. 1.

[0084] FIG. 2 is an alternative implementation of the electrode 110 shown in FIG. 1. The width of the electrodes and the spacing between the electrodes are both 50 μm. The length of the electrodes is 8 mm. In implementations, such dimensions can range from 100 nm to 10 cm, depending on the particular design and application. The shifted design of the electrodes in FIG. 2 helps expose each cell passing through the channel to the electric field, resulting in higher DNA transfection efficiency. In this implementation, the gold electrodes are on the plane of the glass surface (top). However, electrodes can be implemented on the silicon layer (bottom) or both layers (top and bottom). The current electrode configuration (FIG. 2) consists of a series of linear electrodes that change position in the middle of the channel to ensure that any cell passing through the fluid channel below it is exposed to the field. That is, if the cell was moving directly underneath the electrodes, after the shift, the cell will be located between the two electrodes and therefore exposed to the electric field. This consideration is important in ensuring that most (at least 20, 50, 75, 80, 85, 90, 95, 99% or more) or all cells are exposed to the electric field. The shift angle can range from 1 to 90° and can be at any point along the length of the electrodes, such as the midpoint (as shown in FIG. 2) or at 5, 10, 20, 25, 35, 50, 60, 75, 80, 85, 90, 95% or more of the distance between the electrodes. Electrodes can also be mounted perpendicular or at an oblique angle (ranging from 1 to 90°) to the flow of cells.

[0085] The microfluidic platform can be fabricated by etching microfluidic channels into a silicon wafer using deep reactive ion etching. Electrodes are evaporated onto the top of the Pyrex wafer using photolithography and lift-off. The two wafers can then be bonded together, for example, via an anode or another bonding means, to seal the microfluidic channel. In some examples, the electrodes are located on the top (e.g., glass) plate / wafer (i.e., not present on the bottom (silicon wafer); alternatively, the electrodes are located on the bottom plate (not present on the top plate / wafer). In some embodiments, the electrodes are located on both sides of the device, for example, on or within the top and bottom plates or wafers. The horizontal lines in FIG. 2 indicate electrodes that connect to either negative or positive pads (rectangles in the figure). In this configuration, cells flow from left to right under the electrodes located in the glass wafer. To ensure that each cell is exposed to the electric field, the electrodes are offset at certain positions in the electrode configuration (e.g., the gray portions of the electrodes). For example, as shown in FIG. 2, the offset is at an angle of about 1-90°, for example 20-80°, for example about 45°. In this way, cells flowing in a straight line through the microfluidic device are exposed to the electric field at least a small fraction of the time they traverse the entire length of the microfluidic channel.

[0086] The electric field can be, for example, 0.1 kV / m to 2000 kV / m, 10 to 2000 kV / m, or 0.1 kV / m to 100 MV / m, preferably 50 to 500 kV / m. Furthermore, the cells can be exposed to the electric field for a known time. For example, the pulse width is 1 ns to 1 s and the period is 100 ns to 10 s, preferably the pulse width is 0.05 to 0.5 ms and the period is 1 to 20 ms. The strength of the electric field required for delivery can be lower than that of conventional electroporation. As a result, for a given delivery efficiency, the subject matter can require less electric field strength than electroporation. As shown in FIG. 3, the DNA transfection efficiency using the method of the present invention is better than electroporation at different electric field strengths, indicating that a similar or better transfection efficiency can be obtained using a lower electric field strength compared to electroporation alone.

[0087] Electroporation involves a combination of pulse strength and pulse width. For example, in the Neon® transfection system, the pulse is typically 0.3-1 kV.cm, with a pulse width of 5 ms-50 ms. In some embodiments involving an electric field, the electric field strength is similar to that used for electroporation, but the pulse width is much lower than that for electroporation. The use of lower pulse widths results in lower cell exposure to energy and higher viability. Furthermore, despite exposure to lower energy, DNA is delivered to the nucleus (and other regions of the cell) and expression occurs more rapidly than with electroporation alone.

[0088] In an exemplary operation, cells can be transported through the constricted channel 105 at a constant pressure (5 psi to 100 psi). The cells are then contacted with a pulsed electric field activated by an oscillator. In one example, an integrated circuit is used to provide the electrical signal to drive the electrodes. The delivery efficiency of Cascade Blue-labeled 3 kDa dextran molecules, and expression of plasmid DNA for green fluorescent protein (GFP) expression are characterized by flow cytometry to evaluate performance. Results show that the delivery efficiency is 70% for 3K dextran and 63% for DNA transfection, with cell viability maintained at 90%. Such simultaneous delivery of both small and large molecules is difficult with other techniques.

[0089] The subject matter described herein can provide many advantages. For example, gene expression can be significantly increased. In one implementation, gene expression in a device with only a constriction is less than 5% and can be increased to 63% by including an electric field. In some embodiments, gene expression in a device with only a constriction is less than about 1, 2, 3, 4, or 5% and can be increased to about 60-100 or 65, 70, 75, 80, 85, 90, 95, or 100% by exposing squeezed cells to an electric field. Cell Deformation Devices with both a constriction and electrodes are advantageous for different types of payload delivery. For example, such devices can be used to expose cells to a constriction and then to an electric field. By using a single process or device, the system effectively delivers both relatively large and small molecules into the cell. For example, the system is particularly useful for delivering nucleic acids, such as plasmid DNA, encoding gene products to cells and nuclei to achieve expression of the delivered genes. For example, exposure of cells to an electric field after passing through a cell deformation constriction facilitates entry of the plasmid into the nucleus. The approach can also allow for the simultaneous delivery of various substances, such as proteins and nucleic acids. The cell deformation element promotes the disruption of the outer membrane to facilitate delivery of cytoplasmic proteins, and the electric field facilitates potential nuclear disruption to allow electrophoretic entry of substances into the cell.

[0090] FIG. 3 is a bar graph 300 showing DNA transfection rates after 24 hours of incubation of exemplary cells transported through the microfluidic system 100 to deliver payload DNA. The time each cell spends passing through the electric field is 36 mS, with a duration of 0.1 mS and a period of 5 mS for the pulsed electric signal. The cells are suspended in a hypotonic buffer before processing, then injected through the microfluidic chip to be squeezed and passed through the electric field. The cells are then collected and waited for 3 minutes before being added to the medium. The DNA transfection rates are analyzed after 24 hours of incubation using fluorescence activated cell sorting (FACS). The results shown in FIG. 3 show that cell squeezing significantly improves the DNA transfection rate during the passage through the electric field.

[0091] FIG. 4 is a bar graph 400 illustrating cell viability. The time each cell spends passing through the electric field is 36 mS; the duration of the pulse electric signal is 0.1 mS, and the period is 5 mS. The cells are suspended in a hypotonic buffer solution before processing, and then injected through a microfluidic chip to squeeze and pass through the electric field. The cells are then collected, waited for 3 minutes, and then added to the medium. The DNA transfection rate is analyzed after 24 hours of incubation using FACS. The results show that cell squeezing significantly improves the DNA transfection rate during the passage of the electric field.

[0092] FIG. 5 is a line graph 500 showing DNA transfection rate and viability. The time each cell spends passing through the electric field is 24 mS; the duration of the pulsed electric signal is 0.1 mS, the period is 5 mS; and a 10-8X chip is used. The cells are suspended in a hypotonic buffer, mixed with GFP-DNA plasmid and 3 KDa dextran, processed, and then injected through a microfluidic chip to squeeze and pass through an electric field. The cells are then harvested and added to the culture medium after 3 minutes (dashed line) or directly (solid line). The DNA transfection rate is analyzed using FACS after 24 hours of incubation.

[0093] Figure 6 is a bar graph 600 showing how exposure time to such buffer before treatment affects DNA delivery and cell viability. The time each cell spends passing through the electric field is 24 mS; the duration of the pulsed electric signal is 0.1 mS and the period is 5 mS; a 10-8X tip is used. The cells are suspended in a hypotonic buffer and mixed with gfp DNA plasmid and 3 KDa dextran. Exposure times up to 40 minutes are investigated, as shown in Figure 6. The cells are then harvested and added directly (solid line) to the medium. DNA transfection rates are analyzed using FACS after 24 hours of incubation.

[0094] FIG. 7 is a line graph 700 showing that as the cell speed increases, the cell viability also increases, which means that the electric field is mainly responsible for the decrease in cell viability. The time that each cell spends passing through the electric field is 24 mS; the duration of the pulsed electric signal is 0.1 mS and the period is 10 mS; a 10-7X tip is used. The delivery performance is determined by the cell speed, which is controlled by the applied pressure. The cells are suspended in a hypotonic buffer and mixed with the gfp DNA plasmid; after treatment, the cells are added directly to the medium. At higher speeds, the membrane disruption is more intense, but the exposure to the field can be reduced.

[0095] Figure 8A is a schematic diagram of an embodiment of a microfluidic system illustrating a single constriction channel 105. Figure 8B is an illustration of a single constriction channel 105 of a microfluidic system, depicting the depth, width, and length. A cell passes through a constriction point 107, thereby introducing a transient membrane disruption (e.g., a hole) in the cell membrane. The cell passes through an electric field generated by two electrodes 110, and a payload, such as DNA, is delivered into the cytoplasm.

[0096] General definitions and general techniques Unless otherwise defined, all technical and scientific terms used herein should be understood to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, and biochemistry).

[0097] Although some variations have been detailed above, other modifications or additions are possible. For example, the subject matter is not limited to DNA and RNA, but can deliver a wide range of materials, including nanoparticles, proteins, quantum dots, and DNA, to almost any type of cell type with high throughput. In certain embodiments, the DNA or RNA can incorporate modified nucleotides, such as those having chemical modifications to the 2'-OH group of the ribose sugar backbone, including, for example, 2'-O-methyl (2'OMe), 2'-fluoro (2'F) substitutions, and 2'OMe, or 2'F, or 2'-deoxy, or "locked nucleic acid" (LNA) modifications.

[0098] In the description and claims, a connected list of elements or features may be preceded by a phrase such as "at least one" or "one or more." The term "and / or" may be present in a list of more than one element or feature. Unless implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the individually listed elements or features, or a combination of the listed element or feature with the other listed elements or features. For example, "at least one of A and B;," "one or more of A and B;," and "A and / or B" are intended to mean "A alone, B alone, or both A and B," respectively. A similar interpretation is intended for lists containing more than two items. For example, the phrases "at least one of A, B, and C;," "one or more of A, B, and C;," and "A, B, and / or C" are intended to mean "A alone, B alone, C alone, both A and B, both A and C, both B and C, or all of A, B, and C," respectively. Furthermore, use of the phrase "based on" in the specification and claims is intended to mean "based at least in part on," thereby allowing for unrecited features or elements.

[0099] As used herein, the terms "about" and "substantially" in the context of a numerical value or range mean ±10% of the stated or claimed numerical value or range, unless the context requires a more limited range.

[0100] As used herein, "duty cycle" means the ratio of pulse duration to pulse period.

[0101] In its broadest sense, "disruption and field delivery" or "DFE" refers to the delivery of a payload to a cell by combining compression and exposure to an energy field.

[0102] The terms "plasma membrane" and "cell membrane" are used interchangeably herein and refer to the semi-permeable membrane that separates the interior of a cell from the extracellular environment.

[0103] As used herein, an "expression vector" is a DNA or RNA vector that is capable of effecting expression of one or more polynucleotides. Preferably, the expression vector is capable of expressing the polypeptide in a host cell. The expression vector can be either prokaryotic or eukaryotic and is generally a plasmid. The expression vector of the present invention includes any vector that functions (directs gene expression) in a host cell of the present invention, such as one of the prokaryotic or eukaryotic cells described herein, such as a gram-positive, gram-negative, pathogenic, non-pathogenic, symbiont, coccus, bacillus, or spiral bacterial cell; an archaeal cell; or a protozoan, algal, fungal, yeast, plant, animal, vertebrate, invertebrate, arthropod, mammalian, rodent, primate, or human cell. The expression vector of the present invention includes transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the host cell and control the expression of the polynucleotide. In particular, the expression vector of the present invention includes transcription control sequences. Transcription control sequences are sequences that control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those that control transcription initiation, such as promoter, enhancer, operator, and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the cells of the present invention.A variety of such transcription control sequences are known to those skilled in the art.In a preferred embodiment, the method does not include the use of viral vectors such as adenovirus to deliver nucleic acid molecule or construct.

[0104] When a parameter range is provided, it is understood that all integers and tenths within that range are also provided by the present invention. For example, "0.2 to 5 mg" discloses ranges of 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, etc. up to a maximum of 5.0 mg.

[0105] An embodiment of the present invention provides a technique for applying a controlled deformation to a cell for a predetermined time to induce a perturbation in the cell membrane so that a substance can be delivered to the interior of the cell. The deformation can be induced, for example, by mechanical strain or shear-induced pressure. In one example, a microfluidic system comprises structures for controlling and / or manipulating fluids by confining them to small geometrical volumes (e.g., sub-milliliter volumes such as microliters, nanoliters, or picoliters). The microfluidic system can deliver virtually any payload intracellularly into the cell. The system consists of one or more microfluidic channels having a constriction through which the cells pass. Preferably, the cells suspended in a liquid medium are pressure transported through the system and flow through the microfluidic channel. As the cells pass through the constriction, they create a perturbation in their cell membrane, causing a temporary rupture of the membrane, resulting in the uptake of the payload present in the surrounding medium. The constriction is a function of the size of the target cell, but preferably of the same order of magnitude or less of the cell diameter. Multiple constrictions can be arranged in parallel and / or in series. A cellular perturbation is a breach in a cell that allows extracellular material to move into the cell (e.g., through a hole, cleft, gap, opening, pore, gap, gap, perforation). The perturbations (e.g., gaps or holes) generated by the methods described herein do not form as a result of association of protein subunits to form multimeric porous structures such as those generated by complement or bacterial hemolysin. Other embodiments are within the scope of the described subject matter.

[0106] References to "squeezing," "squeezing," "deforming," and the like, of cells refer to a process used to deliver macromolecules directly into the cytosol of cells with minimal cytotoxicity, unless implicitly or explicitly contradicted by the context in which it is used. The principle underlying this approach is the temporary membrane disruption by rapid mechanical deformation, or squeezing, of target cells, which allows for uptake of macromolecules by diffusion in a fluid medium, followed by repair of the cell membrane (see, e.g., U.S. Patent Publication No. 2014 / 0287509, published September 25, 2014, and PCT National Application No. PCT / US2015 / 058489, filed October 30, 2015, the entire contents of each of which are incorporated herein by reference).

[0107] Mitochondrial Disorders Mitochondrial diseases result from dysfunctional mitochondria. Mitochondrial diseases can result from acquired or congenital mutations, for example, in mitochondrial DNA (mtDNA) or nuclear genes encoding mitochondrial components. Disease can result from acquired mitochondrial dysfunction due to side effects of drugs, infections, or other environmental factors. Examples of mitochondrial diseases include mitochondrial myopathies; diabetic nephropathy; some forms of diabetes and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh's syndrome; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogastrointestinal encephalopathy (MNGIE); myoclonus epilepsy with ragged red fibers syndrome (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like events (MELAS); and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

[0108] Delivery of compounds to mitochondria is particularly challenging and unpredictable. Mitochondria reside within cells and have their own outer (and inner) membranes. Treatment options for mitochondrial diseases and tools for modifying mitochondrial function or labeling mitochondria in living cells are limited (Marriage et al., J Am Diet Assoc (2003) 103(8):1029-38; Kolesnikova et al., Hum. Mol. Genet. (2004) 13(20):2519-2534).

[0109] Aspects of the invention relate to methods for preventing or treating mitochondrial diseases involving delivery of compounds (such as nucleic acids) to mitochondria. In some embodiments, the devices and / or methods described herein are used to deliver a nucleic acid construct to a fertilized or unfertilized egg harboring dysfunctional mitochondria. In other embodiments, the nucleic acid construct is delivered to circulating cells (e.g., immune cells) harboring dysfunctional mitochondria taken from the blood of a subject. The construct delivered to the cells harboring dysfunctional mitochondria may include, for example, a recombinant gene expressing a mitochondrial protein that is not produced, produced at insufficient levels, or is missing in the dysfunctional mitochondria. As shown in FIG. 21, nucleic acids delivered using DFE reach both the nucleus and mitochondria. In a preferred embodiment, the nucleic acid is delivered directly to dysfunctional mitochondria within the cell.

[0110] Aspects of the invention also relate to the delivery of compounds to test for mitochondrial disease and / or function. For example, antibodies, organic molecules, or other compounds that modulate mitochondrial function and / or label mitochondria may be delivered to cells using the devices and methods described herein.

[0111] electric field Aspects of the invention relate to the use of lower electric field strengths or shorter exposure to electric fields compared to standard or previously described electroporation parameters. Electroporation parameters have been reported for a number of cell types. See, for example, the information reference for the Neon® transfection system available at www.thermofisher.com / us / en / home / life-science / cell-culture / transfection / transfection---selection-misc / neon-transfection-system / neon-protocols-cell-line-data.html. See also Kim et al., (2008) Biosens Bioelectron, 23(9):1353-1360, the entire contents of which are incorporated herein by reference. For example, the Neon® transfection system may use electric fields of 0.3-1 kv / cm with pulse durations of 5 ms-50 ms. Examples of electroporation parameters for the Neon® transfection system are also provided in the table below. [Table 1]

[0112] A method for delivering compounds and compositions to cells DFE provides a more efficient method for the transfer of nucleic acids compared to standard or previously disclosed electroporation systems. The present invention provides methods, systems, and devices in which an energy field, such as an electric field, transports a payload through a perturbation in a cell membrane caused by a cell deformation constriction, or transports a payload from one location to another within a cell, for example, from the vicinity of the cell membrane to one or more organelles. While some exemplary implementations use electric fields, other transport mechanisms are useful. Transport mechanisms may utilize, for example, one or more of electric fields, magnetic fields, and acoustic fields.

[0113] As used herein, an electrode refers to any electrical conductor that can carry an electric charge and be configured to generate an electric field. Some implementations may include alternative methods and / or structures for generating electric and / or magnetic fields.

[0114] In some embodiments of the present invention, an electric field is used to transport a payload into a cell. It will be understood that those skilled in the art of electrical engineering are familiar with various methods of generating an electric field. Although examples of electric fields are provided throughout the overview and description of the present invention, none of these descriptions should be construed as limiting. For example, the electric field may be generated by electrodes or by means other than electrodes. In embodiments of the present invention, the use of constant or pulsed electric fields is contemplated. The electric field may be a constant current or a direct current pulse current.

[0115] In other embodiments of the invention, a magnetic field is used to transport a payload into a cell. A magnetic field can be generated to exert a force on the cellular payload as the cell moves through the magnetic field. The magnetic field can be produced by an electromagnet, which can have, for example, a coil of insulated wire wound around an iron core. The magnetic field can also be produced by a permanent magnet, for example a ferromagnetic material.

[0116] In magnetofection, a magnetic field can concentrate magnetic particles on the cell surface to enhance an endocytosis-like process for intracellular delivery. In preferred embodiments, the strength of the magnetic field is lower than that required for magnetofection. In some embodiments that include a magnetic field, the magnetic field strength is between 0.01 T and 10 T. The strength of the magnetic field can vary based on many factors, including the magnetic properties of the payload. In a non-limiting example, it can be between 1 and 1000 T / m -1 It is possible to create a magnetic field gradient in the range of

[0117] In additional embodiments of the invention, an acoustic field is used to transport payloads into cells. For example, cells can be contacted with an acoustic field after exiting a cell deformation constriction of the invention. The acoustic field can be generated, for example, by a speaker, transducer, or other similar device. A speaker is a transducer that converts electromagnetic waves into sound waves. A speaker can receive audio input from a device such as a computer or audio receiver. This input can be in either analog or digital format. An analog speaker can simply amplify analog electromagnetic waves into sound waves. Since sound waves are generated in analog format, a digital speaker must first convert the digital input into an analog signal before generating sound waves. Sound waves can be generated at a variety of frequencies and amplitudes. In some implementations, alternating low and high pressure waves in a buffer or other liquid result in the formation and collapse of small vacuum bubbles, which can be referred to as cavitation. Cavitation causes high velocity impinging liquid jets and powerful hydrodynamic shear forces that can be utilized to manipulate payloads and cells. In some embodiments, sonication is used to generate the acoustic field.

[0118] In some embodiments of the acoustic field, the acoustic energy intensity is, for example, between 1 and 1000 J / cm. 2 However, the energy used may be greater than this range depending on factors such as exposure time, cell type, solution or buffer used, cavitation size, etc. It may be low or high. Non-limiting examples of frequencies include 10 KHz to 10 MHz.

[0119] In other embodiments of the invention, optical fields are used to deliver payloads into cells. For example, visible electromagnetic radiation may be used to deliver substances into cells after the cells have exited the cell deformation constriction of the invention. Examples of visible electromagnetic radiation sources include light emitting diodes (LEDs), lasers, and incandescent light bulbs.

[0120] CAR T cells By engineering T cells to express chimeric antigen receptors (CARs) that recognize cancer-specific antigens, they can recognize and kill tumor cells that have evaded immune detection. The process involves extracting the patient's T cells, transfecting them with the gene for the CAR, and then reinfusing the transfected cells back into the patient.

[0121] These artificial T cell receptors (also known as chimeric T cell receptors, chimeric immune receptors, or CARs) are engineered receptors that confer any specificity to immune effector cells. Typically, these receptors are used to confer the specificity of monoclonal antibodies to T cells. Prior to the present invention, the introduction of nucleic acid coding sequences was typically facilitated by retroviral vectors. The methods described herein do not utilize or involve viral vectors. Cell squeezing by the described device is used to deliver coding sequences or protein CARs to the cytosol of immune cells, such as T cells, without the need for viral vectors.

[0122] In therapeutic applications, T cells from a patient are harvested (and optionally enriched or purified) from peripheral blood and engineered to express an artificial (chimeric) receptor specific for a particular cancer-associated antigen. Once engineered, the T cells recognize and kill the cancer. For example, an exemplary CAR recognizes CD19, an antigen expressed in B-cell malignancies. After engineering the T cells to express the CAR, the engineered T cells are reinfused into the patient. The engineered cells recognize and kill the cancerous cells. Such treatments have been used for ALL, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia (CLL), and are suitable for the treatment of any type of cancer, including blood-borne cancers such as leukemia, B-cell malignancies (e.g., acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia), and solid tumors. The cell processing methods described herein represent an excellent process for generating CAR T cells.

[0123] In some embodiments, the patient is a human. In other embodiments, the patient is non-human.

[0124] Exemplary embodiments An aspect of the invention provides a microfluidic system for inducing a perturbation in a cell membrane, the system comprising a microfluidic channel defining a lumen and configured to allow passage of a cell suspended in a buffer through the lumen, the microfluidic channel having a cell-deforming constriction, the diameter of the constriction being a function of the diameter of the cell, and the system comprising: (a) an energy field; or (b) a source or emitter of the energy field located downstream, upstream, or upstream and downstream of the constriction.

[0125] Aspects of the invention also provide a microfluidic system for delivering a payload to a cell, the system comprising a microfluidic channel defining a lumen and configured to allow passage of a cell suspended in a buffer through the lumen, the microfluidic channel having a cell-deforming constriction, the diameter of the constriction being a function of the diameter of the cell, and the system comprising: (a) an energy field; or (b) a source or emitter of the energy field located downstream of the constriction.

[0126] In some embodiments, the energy field comprises an electric field and the source emitter comprises an electrode. In certain embodiments, the energy field comprises a magnetic field and the source or emitter comprises a magnet or electromagnet. In various embodiments, the energy field comprises (a) an acoustic field and the source or emitter comprises a speaker, or (b) an optical field and the source or emitter comprises a light emitting diode (LED), a laser, or an incandescent light bulb.

[0127] In various embodiments, (a) the diameter of the constriction is selected to induce a transient perturbation of the cell membrane large enough to allow a payload to pass through, and the cells pass through the constriction to reach the field in a continuous flow, and after passing through the constriction, the cells contact or pass through a portion of the field that has sufficient strength to transport the payload via the transient perturbation; or (b) after passing through the constriction, the cells enter and reside within a zone of the device downstream of the constriction, in which the cells contact the field.

[0128] In certain embodiments, the microfluidic channel is one of a plurality of parallel microfluidic channels in a microfluidic system, each microfluidic channel of the plurality of parallel microfluidic channels defining a lumen and configured to allow passage of cells suspended in a buffer through the lumen, each microfluidic channel having a cell-deforming constriction, the diameter of the constriction being a function of the diameter of the cell.

[0129] In some embodiments, the multiple parallel microfluidic channels comprises at least about 2, 5, 10, 20, 25, 30, 40, 45, 50, 75, 100, 500, 1,000, or between 2 and 1,000 microfluidic channels.

[0130] In various embodiments, the diameter of the constriction is selected to induce a transient perturbation of the cell membrane large enough to allow the payload to pass through.

[0131] In certain embodiments, the electrodes include two electrodes that generate an electric field to transport a payload into cells suspended in a buffer solution.

[0132] In some embodiments, the payload comprises one or more of: (a) deoxyribonucleic acid (DNA); (b) ribonucleic acid (RNA); (c) DNA or RNA containing one or more modified nucleotides that increase the stability or half-life of the DNA or RNA in vivo or in vitro; (d) peptide nucleic acid (PNA); (e) methylated DNA; (f) naturally occurring chromosomes or portions thereof; (g) expression vectors; (h) proteins; (i) small molecules; (j) sugars; (k) polymers of biological, synthetic, organic, or inorganic molecules; (l) charged molecules or compositions containing charged molecules; or (m) uncharged molecules. For example, any one of (a)-(m) or any mixture thereof may be delivered to a cell. In certain embodiments, the payload is a polypeptide containing a localization signal.

[0133] In various embodiments, the microfluidic systems of the present invention may further include a plurality of electrode pairs with different electrode sizes for each electrode pair.

[0134] In some embodiments, the microfluidic system comprises (a) a plurality of electrodes arranged in at least a first and a second electrode array, where the first electrode array is offset relative to the second electrode array, or (b) a plurality of electrode pairs arranged in at least a first and a second electrode pair array, where the first electrode pair array is offset relative to the second electrode pair array. In various embodiments, the first array is offset by about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, , 40, 45, 50, 55, 60, 70, 80, 90, 1-10, 1-20, 1-30, 1-45, or 1-90° offset.

[0135] In certain embodiments, the microfluidic system of the present invention further comprises an oscillator, which is coupled to at least one electrode and drives the at least one electrode to generate an electric field to transport a payload to the cell suspended in the buffer solution after the cell has contracted through the cell deformation constriction; or the oscillator drives the at least one electrode by induction to generate an electric field to transport a payload to the cell suspended in the buffer solution after the cell has contracted through the cell deformation constriction.

[0136] In some embodiments, the generator is configured to drive at least one electrode to generate an electric field having a strength of about 0.1-0.5, 0.1-1, 0.1-1.5, 0.1-2, 0.1-2.5, 0.1-3 kV / cm, 1-3 kV / cm, 0.1-10 kV / cm, 10-200 kV / m, or 10-2000 kV / m.

[0137] In various embodiments, the microfluidic systems of the present invention include a cell transport portion that transports cells under pressure through a cell deformation constriction.

[0138] In certain embodiments, a fluid stream of cells suspended in a buffer is forced through a constriction, whereby the cells are compressed primarily by the fluid stream.

[0139] In some embodiments, the diameter of the constriction is about 20-99% of the diameter of a cell passing therethrough.

[0140] In certain embodiments, the diameter of the constriction is about 4, 5, 6, 7, 8, 9, 10, 15, 20 4-10 μm, or 10-20 μm, and / or the length of the constriction is about 10, 15, 20, 24, 30, 40, 50, 60, 10-40, 10-50, 10-60, or 10-40 μm.

[0141] In various embodiments, the microfluidic channel has a single cell deformation constriction or multiple cell deformation constrictions in series.

[0142] In some embodiments, the cells are contacted with the electric field about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, or 0.0001-10 seconds after, or within about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 0.01, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, or 0.0001-10 seconds after exiting the cell deformation constriction.

[0143] In certain embodiments, the electric field has a strength of about 0.1-0.5, 0.1-1, 0.1-1.5, 0.1-2, 0.1-2.5, 0.1-3 kV / cm, 1-3 kV / cm, 0.1-10 kV / cm, 10-200 kV / m, or 10-2000 kV / m.

[0144] An embodiment of the invention provides a method for delivering a compound or composition to a cell, the method comprising providing cells in a payload-containing solution; passing the solution through a microfluidic channel having a cell-deforming constriction; passing the cells through the constriction, thereby applying pressure to the cells to cause a perturbation of the cell membrane large enough to allow the payload to pass through the cell membrane and enter the cytosol of the cell; contacting the cells with an electric, magnetic, acoustic, or optical field, thereby transporting the payload from a first location within the cell to a second location within the cell.

[0145] An embodiment of the invention also provides a method of delivering a compound or composition to a cell, the method comprising providing cells in a payload-containing solution; passing the solution through a microfluidic channel having a cell-deforming constriction; passing the cells through the constriction, whereby the passage induces a perturbation of the cell membrane large enough to cause the payload to pass through the cell membrane and enter the cytosol of the cell; contacting the cells with an electric, magnetic, acoustic, or optical field, thereby transporting the payload from a first location within the cell to a second location within the cell.

[0146] An embodiment of the invention provides a method for delivering a compound or composition to a cell, the method comprising providing cells in a payload-containing solution; passing the solution through a microfluidic channel having a cell-deforming constriction; passing the cells through the constriction, thereby applying pressure to the cells to cause a perturbation of the cell membrane large enough to cause the payload to pass through the cell membrane and enter the cytosol of the cell; and contacting the cells with an electric, magnetic, acoustic, or optical field, thereby transporting the payload into the cell.

[0147] In some embodiments, the cells are contacted with a magnetic field, the magnetic field being generated by at least one electromagnet. In various embodiments, the cells are contacted with an electric field, the electric field being generated by one or more electrodes.

[0148] In certain embodiments, cells are passed through a microfluidic channel in a first device, then removed from the first device and contacted with an electric, magnetic, or acoustic field in a second device.

[0149] In various embodiments, the microfluidic channels and the electric, magnetic, and acoustic fields are in one device.

[0150] In some embodiments, (a) cells enter the field in a continuous flow through a constriction and, after passing through the constriction, contact or pass through a portion of the field that has sufficient strength to transport a payload via a transient perturbation; or (b) after passing through the constriction, the cells flow into and reside in a zone of the device where they contact the field.

[0151] In certain embodiments, the cell is a plurality of cells, each cell passing through one of a plurality of parallel microfluidic channels, each microfluidic channel of the plurality of parallel microfluidic channels having a cell deformation constriction where the plurality of cells pass through an electric field.

[0152] In various embodiments, the diameter of the constriction is selected to induce a transient perturbation of the cell membrane that is large enough to allow the payload to pass when transported by the electric field.

[0153] In some embodiments, the payload comprises one or more of: (a) deoxyribonucleic acid (DNA); (b) ribonucleic acid (RNA); (c) DNA or RNA containing one or more modified nucleotides that increase the stability or half-life of the DNA or RNA in vivo or in vitro; (d) peptide nucleic acid (PNA); (e) methylated DNA; (f) naturally occurring chromosomes or portions thereof; (g) expression vectors; (h) proteins; (i) small molecules; (j) sugars; (k) polymers of biological, synthetic, organic, or inorganic molecules; (l) charged molecules or compositions containing charged molecules; or (m) uncharged molecules. For example, any one of (a)-(m) or any mixture thereof may be delivered to a cell. In certain embodiments, the payload is a polypeptide that includes a localization signal.

[0154] In certain embodiments, a cell is contacted with an electric field and a payload is delivered to one or more of: (a) the nucleus of the cell; (b) the mitochondria of the cell; or (c) an organelle of the cell other than the nucleus or mitochondria of the cell.

[0155] In various embodiments, the cells are contacted with an electric field and the payload is transported into the nucleus of the cells while the cells are passing through the electric field or less than 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 48 hours after the cells are passing through the electric field.

[0156] In some embodiments, the cell is a plurality of cells, the payload is DNA that is expressed when in the cell nucleus, and at least about 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99, 100, 0-65, or 10-100% of the cells of the plurality of cells express the DNA within about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 0.1-4, or 0.1-48 hours after the plurality of cells passes through the electric field.

[0157] In certain embodiments, an electric field is generated by two electrodes to transport a payload into cells suspended in a buffer solution.

[0158] In various embodiments, the electric field is generated by multiple electrode pairs with varying electrode sizes for each electrode pair.

[0159] In some embodiments, at least one electrode is driven by an oscillator coupled to the electrode, which drives the electrode to generate an electric field for delivering a payload to the cell suspended in a buffer solution after the cell has been constricted by the cell deformation constriction.

[0160] In certain embodiments, a fluid stream of cells suspended in a buffer is forced through a constriction, whereby the cells are compressed primarily by the fluid stream.

[0161] In some embodiments, the diameter of the constriction is about 20-99% of the diameter of a cell passing therethrough. In some embodiments, the diameter of the constriction is about 4, 5, 6, 7, 8, 9, 10, 15, 20 4-10 μm, or 10-20 μm. In some embodiments, the length of the constriction is about 10, 15, 20, 24, 30, 40, 50, 60, 10-40, 10-50, 10-60, or 10-40 μm. In some embodiments, the cells contact the electric field about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, or 0.0001-10 seconds after exiting the cell deformation constriction, or the cells contact the electric field within about 0.0001, 0.001, 0.002, 0.003, 0.004, 0.005, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 0.001-0.005, or 0.0001-10 seconds after exiting the cell deformation constriction. In some embodiments, the exposure time of the cells to the electric field is about 10-50 ms, 50-100 ms, or 10-100 ms. In some embodiments, the electric field is constant. In some embodiments, the electric field is a constant current or a direct pulsed current. In some embodiments, the electric field is pulsed. In some embodiments, the electric field is pulsed for about 50-200 μs. In some embodiments, the electric field strength or pulse strength is about 1-3 kV / cm or 0.1-10 kV / cm, or 0.1-0.5, 0.1-1, 0.1-1.5, 0.1-2, 0.1-2.5, or 0.1-3 kV / cm. In some embodiments, the electric field strength or pulse strength is less than the strength required to electroporate the cells. In some embodiments, the pulse width is less than the pulse width required to deliver an equivalent amount of payload to a corresponding cell. In some embodiments, the electric field strength or pulse strength is about 50, 1-50, 50-99, or 1-99% less than the strength required to electroporate the cells. In some embodiments, a pressure of about 10-35 psi is used to pass the solution through the microfluidic channel.In some embodiments, cells pass through the microfluidic channel at a speed of about 300, 100-300, 200-700, 250-400, 100-1000 mm / s, or 1-1000 mm / s. In some embodiments, the microfluidic channel accommodates multiple cell transformers in series. In some embodiments, the microfluidic channel has a single cell deformation constriction. In some embodiments, the cells are a plurality of cells, and about 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 90-95, or 80-100% of the cells are viable after passing through the electric field. In some embodiments, the strength or pulse strength of the electric field is about 10-2000 kV / m, or less than 100 kV / m. In some embodiments, the electric field is pulsed for a duration of about 0.1, 0.1-2, or 0.1-2000 ms, with a period of 1-20, 0.1-2000, or 1-200 ms. In some embodiments, the cells pass through the electric field at a speed of about 100, 170, 300, 100-300, 200-700, 250-400, 100-1000 mm / s, or 1-1000 mm / s. In some embodiments, the cell membrane perturbations have a maximum diameter of about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm. In some embodiments, the perturbation of a cell membrane having a maximum diameter of about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm persists within the cell membrane for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 1-10 minutes.

[0162] In various embodiments, the cell is a prokaryotic or eukaryotic cell. In certain embodiments, the cell is an erythrocyte, a T cell, a B cell, a neutrophil, a dendritic cell, a macrophage, a monocyte, a NK cell, an ILC, or any combination thereof.

[0163] An embodiment of the invention provides a method for delivering an expression vector encoding a transgene to a cell, the method comprising: passing a solution comprising the cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells to cause a perturbation of the cell membrane large enough to allow the expression vector to pass; passing the solution through an electric field generated by at least one electrode to transport the expression vector into the cell, where the transgene is expressed at a faster rate compared to expression of the transgene in cells that have passed through the electric field without passing through the cell deformation constriction.

[0164] In some embodiments, the transgene is expressed 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1-4 hours earlier compared to expression of the transgene in corresponding cells contacted with the electric field without passing through the cell deformation constriction.

[0165] An embodiment of the invention also provides a method for delivering an expression vector encoding an introduced gene to a cell, the method comprising: passing a solution comprising a cell and the expression vector through a cell deformation constriction, thereby applying pressure to the cell to cause a perturbation of the cell membrane large enough to allow the expression vector to pass; passing the solution through an electric field generated by at least one electrode to transport the expression vector into the cell, wherein maximum expression of the introduced gene in the cell is achieved or detected at a faster rate than said expression in cells that have passed through the electric field without passing through the cell deformation constriction.

[0166] In some embodiments, expression of the transgene in the cells is achieved about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours earlier than such expression in corresponding cells contacted with an electric, magnetic, or acoustic field without passing through a cell deformation constriction.

[0167] Aspects of the invention also provide a method for delivering an expression vector encoding a transgene to a cell, the method comprising passing a solution containing the cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells and causing a perturbation of the cell membrane large enough to allow the expression vector to pass through. straining; passing a solution through an electric field generated by at least one electrode to transport an expression vector into cells, where the transgene is more widely expressed in the cells compared to expression in cells that have been passed through an electric field without passing through a cell-deforming constriction.

[0168] In some embodiments, after a cell has passed through a constriction and contacted the field, the expression level of the transgene is greater than the expression level in a corresponding cell that passed through the electric field without passing through a cell deformation constriction.

[0169] In various embodiments, expression of the transgene in the cells is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than expression of the transgene in corresponding cells contacted with the electric field without passing through a cell deformation constriction.

[0170] In some embodiments, expression of the transgene in a cell within about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or within 0.1-4 hours after the cell has passed through the constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than expression of the transgene in a corresponding cell contacted with the electric field without passing through a cell deformation constriction.

[0171] An aspect of the invention provides a method for delivering an expression vector encoding a transgene to a cell population, the method comprising: passing a solution comprising cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells to cause a cellular perturbation large enough to allow the expression vector to pass; passing the solution through an electric field generated by at least one electrode to transport the expression vector into the cells, wherein a proportion of cells in the population expressing the transgene is greater than a proportion of cells expressing the transgene in the cell population that passed through the electric field without passing through the cell deformation constriction.

[0172] In some embodiments, the percentage of cells expressing the transgene in the population is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of cells expressing the transgene in a corresponding cell population contacted with the electric field without passing through a cell deformation constriction.

[0173] In some embodiments, the percentage of cells expressing the transgene in a population within about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or within 0.1-4 hours after the cells have passed through a constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of cells expressing the transgene in a corresponding cell population contacted with the electric field without passing through a cell deformation constriction.

[0174] Aspects of the invention also provide a method of delivering an expression vector encoding a transgene to a cell population, the method comprising: passing a solution comprising cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells to cause a cellular perturbation large enough to allow the expression vector to pass; passing the solution through an electric field generated by at least one electrode to transport the expression vector into the cells, wherein a proportion of cells in the population that express a high level of the transgene is greater than or equal to a proportion of cells in the population that pass through the electric field without passing through the cell deformation constriction. It is greater than the proportion of cells that express a gene at high levels.

[0175] In certain embodiments, the percentage of cells in a population expressing high levels of the transgene is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of cells expressing the transgene in a corresponding cell population contacted with the electric field without passing through a cell deformation constriction.

[0176] In some embodiments, the percentage of cells in a population expressing high levels of the transgene within about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or within 0.1-4 hours after the cells have passed through a constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of cells expressing the transgene in a corresponding cell population contacted with an electric field without passing through a cell deformation constriction.

[0177] An aspect of the invention provides a method for delivering an expression vector encoding a transgene to a cell, the method comprising: passing a solution comprising the cells and the expression vector through a cell deformation constriction, thereby applying pressure to the cells to cause a perturbation of the cell membrane large enough to allow the expression vector to pass; passing the solution through an electric field generated by at least one electrode to transport the expression vector into the cell, where the transgene is expressed more rapidly in the cell than expression of the transgene in cells that have passed through the electric field without passing through the cell deformation constriction.

[0178] In various embodiments, the transgene is expressed about 0.1, 1.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1-4 hours earlier than corresponding cells contacted with an electric field without passing through a cell deformation constriction. EXAMPLES

[0179] Example 1: Microfluidic platform for DNA delivery Many techniques for DNA transfection have been developed. Carrier-based methods such as lipofection are highly dependent on the interaction of the carrier with the cell membrane and the intracellular transport of DNA, a biologically active process. Microinjection has been used to deliver DNA directly into the nucleus for transcription, but is limited by throughput. Electroporation is widely used for DNA transfection, but its mechanism remains controversial and is also limited by its reliance on active DNA transport from the plasma membrane to the nucleus after an electric pulse. Here, we describe a concept of intracellular delivery that we term disruption and field-mediated delivery (DFE; this term is not limited to the embodiment of this example). In DFE, disruption first opens perturbations in the plasma membrane, which then allows DNA delivery through these gaps into the cytoplasm and nucleus. This strategy involves the combination of mechanical disruption and electric fields to deliver cargo molecules, such as GFP plasmid DNA, or mixtures thereof, directly into the nucleus and express within 1 hour of treatment, which is more rapid than other methods such as electroporation. This novel strategy is useful for intracellular gene delivery to hard-to-transfect cells and for co-delivery of a wide range of substances.

[0180] Cell transfection is essential for many tests in biology and medicine. Various techniques have been developed for cell transfection, including biological, chemical, and physical methods. Biological / chemical methods usually rely on carriers such as viruses, vesicles, peptides, or nanoparticles (Nayak et al., Gene Ther. 17, 295-304 (2010); Wu et al., Biotechnol. Progr. 18, 617-622 (2002); Schmid et al., Gut 41, 549-556 (1997); Lee et al., Nat. Nanotechnol. 7, 389-393 (2003)). (2012)). Physical methods primarily use membrane disruption techniques for gene delivery, including microinjection, electroporation, laser poration, and biolistics (O'Brien & Lummis, Nature Protoc. 1, 977-981 (2006); Wells, DJ Gene Ther. 11, 1363-1369 (2004); Meacham et al., J. Lab. Autom. 19, 1-18 (2014); Capecchi, Cell 22, 479-488 (1980); Nagy et al., Manipulating the Mouse Embryo: A Laboratory Manual (Cold Spring Laboratory, 2003)). Naked nucleic acid delivery into cells is likely to be the safest and most robust approach for cell transfection (Wolff & Budker, Advances in Genetics, 54, 3-20 (2005)). Among the physical methods capable of delivering naked genetic material, electroporation is by far the most widespread method due to its simplicity, reasonably good efficiency, and ability to address certain challenging primary cells (Neumann et al., EMBO J. 1, 841-845 (1982)). Since its first report in the early 1980s, electroporation, also known as electroosmosis, has been widely used for intracellular delivery of nucleic acids to many different cells in biological and medical applications. Although electroporation has demonstrated its advantages and is widely used for DNA transfection, its underlying delivery mechanism is not fully understood (Escoffre et al., Mol. Biotechnol. 41, 286-95 (2009); Vasilkoski et al., Phys. Rev. E 74, 021904 (2006); Klenchin et al., Electrically induced DNA uptake by cells is a fast process involving DNA electrophoresis.60,(1991);Weaver et al.,Bioelectrochemistry 87,236-43(2012);Jordan et al.(Eds.)(2013) Electroporation and electrofusion in cell biology. Springer Science&Business Media). It is widely accepted that in the electroporation process, DNA molecules accumulate during the electric pulse and interact with the electropermeable plasma membrane. These DNA aggregates are then internalized into the cytoplasm and subsequently cause gene expression (Golzio et al., Proc. Natl. Acad. Sci. 99, 1292-1297 (2002); Paganin-Gioanni et al. Proc. Natl. Acad. Sci. USA 108, 10443-7 (2011); Rosazza et al. al.Mol.Ther.21,2217-2226(2013);Boukany et al.,Nat.Nanotechnol.6,747-54(2011);Teissie et al.,Biochim.Biophys.Acta 1724,270-80(2005);Yarmush et al. al., Annu.Rev.Biomed.Eng.16,295‐320(2014);Geng&Lu,Lab Chip 13, 3803-21 (2013)). It is unlikely that DNA plasmids can reach the nucleus simply by diffusion through the viscous and dense cytoplasm (Lechardeur et al., Adv. Drug Deliv. Rev. 57, 755-767 (2005); Dowty et al., Proc. Natl. Acad. Sci. USA 92, 4572-4576 (1995)). Several studies have shown that the transport of DNA from the plasma membrane to the nucleus is an active biological process by cytoskeletal transport, such as through the microtubule and actin networks (Rosazza et al. Mol. Ther. 21, 2217-2226 (2013)). It has been found that the microtubule and actin networks play an important role in DNA transport within the cytoplasm and that the time scale of such processes can be long depending on the cell type. The unclear mechanism and complex nature of DNA transport between the plasma membrane and the nucleus hinders further application and improvement of electroporation to hard-to-transfect cells. Moreover, the strong electric fields used in current electroporation methods can cause severe damage or cell death (Yarmush et al. al., Annu. Rev. Biomed. Eng. 16, 295-320 (2014); Geng & Lu, Lab Chip 13, 3803-21 (2013)), but the DFE described herein circumvents this problem. In this regard, there is great interest in developing a technique that can directly transfer naked DNA into the nucleus without relying on poorly defined transport pathways. Conventional methods or approaches are often technically complex, have relatively low throughput, and lack compatibility with certain primary cells.

[0181] High-throughput, efficient delivery of DNA to the nucleus Herein, we disclose an example of the development of the concept of disruption and delivery by field (DFE). In this approach, the cell membrane is first disrupted by a mechanical process, and then the cell is exposed to a field to transport the material to the target cell. A microfluidic device has been developed that can deliver DNA directly to the nucleus of a cell in a high-throughput manner. One implementation of the DFE concept involves temporarily disrupting the cell membrane using cell squeezing, followed by exposing the cell to an electric field, thereby transporting the negatively charged DNA through a membrane disruption, e.g., the nuclear membrane or mitochondrial membrane, and delivering the carto to the cell cytosol and then into the cell nucleus. The CellSqueeze technology has demonstrated a robust ability to deliver a variety of materials across a range of cell types, but is not effective alone in facilitating nuclear delivery of DNA (Shalek et al., 2013). al., Proc. Natl. Acad. Sci. USA 107, 1870-5 (2010)). Unlike electroporation, where DNA molecules electrophoretically move towards and condense on the plasma membrane, in the DFE process DNA molecules move into and / or within the cell through perturbations or gaps in the cell membrane caused by mechanical disruption. See, e.g., FIG. 9A. This combined process (DFE) results in synergistic effects in the delivery of cargo, e.g., charged compounds, e.g., DNA, to the cytosol and subcellular structures. The synergistic effects are demonstrated by measuring the function of the delivered cargo, e.g., gene expression by the delivered DNA.

[0182] This example describes a unique microfluidic device that can deliver DNA directly into the nucleus in a high-throughput manner by combining mechanical disruption and exposure to an electric field. The cell squeezing technique has been found to be an efficient technique to mechanically disrupt the plasma membrane. As cells flow through a constricted channel with a minimum dimension smaller than the cell diameter, the temporary deformation creates holes in the plasma membrane through which surrounding materials can diffuse directly into the cell's cytosol.

[0183] As shown in Figures 9A-C, each device is integrated with a set of parallel and identical constriction channels and a set of electrodes. In the experiments described in this example, 75 parallel channels were etched into a silicon wafer using DRIE (deep reactive ion etching) and sealed by anodic bonding of Pyrex patterned with electrodes (see Figure 13 for fabrication details). The width and length of the constrictions range from 4 to 10 um and 10 to 30 um, respectively. The length, width, and gap space between each electrode are 8 mm, 60 um, and 40 um, respectively. The duration and duty cycle of the electrical pulses applied to the devices range from 50 to 200 us and 1 to 5%. The method of the present invention can be operated at very high throughput. For example, cells can be processed at a throughput of at least about 10,000, 20,000, 30,000, 40,000, 50,000, 100,000, 200,000, 300,000, 400,000, 500,000, 1,000,000, or 1-1,000,000 cells / s. The mixture of cells and the desired substance is transported to the inlet by gas pressure, e.g., nitrogen pressure, controlled by a regulator. An electric pulse is applied to the device when the sample is placed in the device, thereby exposing the cells to the electric field immediately after squeezing. The exposure time of the cells to the electric field is usually in the range of 10-50 ms depending on the flow rate.

[0184] To investigate the mechanism of DNA delivery, model cells and A number of experiments were performed using 100-well plates and model cargo to characterize the performance of the DFE technology. A mixture of HeLa cells and GFP plasmid DNA was treated with the DFE device using different pulse amplitudes. The cells were then incubated at 37C for 24 hours. DNA expression was characterized by measuring GFP fluorescence using flow cytometry. A DFE10-6 device was used in this experiment. DFE10-6 refers to the constriction dimensions of the DFE device, where the first number corresponds to the length of the constriction and the second number corresponds to the width (in microns). The two governing parameters that affect the performance of mechanical disruption are cell speed and constriction dimensions, while the three governing the performance of the electric field are the electric pulse profile, intensity, and number of pulses (which depend on the cell speed in the channel). First, we investigated how pulse intensity affects DNA transfection. With the DFE10-6 treatment, the cell transfection rates are greater than 60% and 90% when the applied amplitude is increased to 8V and 10V, respectively, as shown in the red columns in Figure 10A. As a control group, cells were treated with a device with comparable electric field and cell velocity, but without the constriction structure (velocity, not pressure, was controlled in this experiment). In the design where cells are only subjected to the electric field and not mechanical disruption, the DNA transfection efficiency reaches 60% after increasing the applied amplitude to 14V. As shown in Figure 10B, both cases share comparable cell viability, indicating that at lower electric field strengths, mechanical disruption dramatically enhances DNA delivery while causing little damage to cells. Mechanical disruption of the plasma membrane facilitates the subsequent electrical transfection process.

[0185] The effect of cell speed on transfection was also investigated. For example, as shown in Figure 14, under 10V applied pulses, increasing cell speed reduces DNA expression due to the reduced number of pulses the cells receive as they pass through the electric field. A desirable balance between cell viability and DNA expression was achieved at cell speeds near 300 mm / s. These exemplary conditions balance the potentially severe effects of electrical damage at low speeds and mechanical damage at high speeds. The efficiency of delivery of membrane-impermeable Cascade Blue-labeled 3 kDa dextran molecules into viable HeLa cells first decreases and then increases with increasing cell speed, indicating that the potentially dominant role of delivery of this molecule switches from mechanical disruption to electric field and then back to mechanical disruption. The difference in behavior between 3 kDa dextran and DNA further highlights the importance of the electric field effect on DNA.

[0186] To further explore the mechanism of DFE delivery, a comparative study was performed on the ability to transfect HeLa cells with GFP plasmid DNA using DFE and four other widely used DNA transfection techniques, namely microinjection, lipofectormine 2000, ME (microfluidics (no squeezing) + electric field) and BEP (bulk electroporation using the NEON electroporation system, a common commercial electroporation tool). As shown in Figure 11, after treatment with each technique, GFP expression was analyzed using flow cytometry. BEP and ME showed similar expression kinetics, as GFP was gradually expressed within the first 24 hours after treatment. 70% of the transfected cells expressed GFP between 4 and 48 hours. However, with microinjection and DFE, more than 80% of the cells expressing GFP (cells expressing GFP fluorescence after 48 hours) showed measurable expression within 1 hour after treatment, indicating that DNA transcription / translation occurs immediately after treatment. The remaining 20% ​​of cells that ultimately express GFP (cells expressing GFP after 48 hours) had detectable expression 1 to 4 hours after treatment. Microinjection is widely accepted as a means to facilitate direct injection of material into the nucleus. The fact that microinjection and DFE share similar DNA expression kinetics is strong evidence that DNA delivered by DFE is immediately available for transcription in the nucleus. In contrast, with lipofection (Lipofectamine 2000), minimal GFP fluorescence was observed in the first 4 hours after treatment, and over 95% of transfected cells expressed GFP 4 to 48 hours after treatment. GFP-expressing cells by DFE, BEP, and lipofection Fluorescence images of the vesicles are shown in Figure 15. To better understand the mechanism of DFE, the fluorescence intensity of GFP expressed in HeLa cells was statistically compared, as shown in Figure 16. In BEP, the translocation to the nucleus and subsequent transcription required more time, and GFP fluorescence increased over 24 hours. The fluorescence intensity of most of the transfected cells began to increase immediately after treatment and saturated within 6 hours, indicating that DNA transcription occurred from a starting point equivalent to that when DNA was delivered into the nucleus.

[0187] To further investigate the mechanism of action of DNA transfer, the distribution of DNA was directly visualized at the single-cell level using CY3-labeled plasmid DNA. First, cells were incubated in the presence of DAPI and Cell Mask green plasma membrane stain for nuclear and membrane staining, then mixed with labeled DNA, immediately followed by DFE, BEP, and mechanical disruption treatments. After treatment, cells were incubated in medium for 2 min and then fixed using a cell fixation kit. Optical measurements were performed using a Nikon A1R confocal microscope. Application of a 15 ms / 1200 V electric pulse, known to permeabilize cells, resulted in a clear appearance of CY3 fluorescence at the cell membrane level. This indicated the absorption and accumulation of DNA on the membrane. This result was consistent with previous studies showing asymmetric embedding of DNA in the plasma membrane. Although previous studies based on flow cytometry showed some delivery of labeled DNA, mechanical disruption showed little or no fluorescent detection of labeled DNA in the cytoplasm, even with confocal microscopy. In DFE, the fluorescence of the labeled DNA was found to be distributed in the cytoplasm, nucleus, and plasma membrane. Interestingly, while BEP had a unipolar character, the DNA in the plasma membrane was distributed in a bipolar manner, potentially indicating a pathway for the labeled DNA to enter and leave the cell during exposure to an electric field. The direct visualization of DNA in the cytoplasm and nucleus further indicates that DFE can more effectively deliver DNA directly to the nucleus. Such results demonstrate that DFE provides a more powerful means to facilitate the efficient delivery of functional materials to the cytosol, nucleus, and other organelles in cells.

[0188] Intracellular delivery is a challenging process that plays a key role in diverse applications. Liposome and nanoparticle-based methods have difficulty transferring primary cells or non-nucleic acids, electroporation has toxicity issues and is ineffective for non-highly charged macromolecules, and mechanical disruption methods can have difficulty providing adequate nuclear delivery. DFE combines the effectiveness of mechanical membrane disruption with the transport power of the field to facilitate nuclear delivery of charged cargo such as nucleic acids, e.g., plasmids, while maintaining the robust delivery capability of mechanical disruption.

[0189] The transport of DNA from the plasma membrane to the nucleus and subsequent transcription is a complex and likely more active process that may take several hours and may vary dramatically between different cell types. This process is essential in carrier-based methods such as electroporation and lipofection and is believed to hinder DNA transfection of difficult-to-transduce cells such as immune cells and stem cells. The data described herein show that DFE directly delivers DNA to the cytoplasm and nucleus by combining mechanical disruption and electric fields. First, cells were passed through a microchannel with a constriction, resulting in perturbations on the plasma membrane. While not wishing to be bound by any scientific theory, the results show that subsequent exposure to an electric field transports the surrounding DNA to the cytoplasm and nucleus. The mechanism of action of DFE was investigated and tested at the single cell and statistical levels using HeLa cells, GFP plasmid DNA, and Cy3 fluorescently labeled plasmid DNA. This is the most rapid naked DNA plasmid expression in a high-throughput setting shown without the assistance of a carrier. The visualization of the DNA transcription process using different techniques was compared. The dynamics of DNA expression by lipofection in Figure 10 show that DNA transfer to the nucleus and subsequent transcription takes more than 4 hours in HeLa cells. DNA expression by conventional electroporation is slightly faster. There is ongoing debate as to whether this mechanism occurs. Some believe that an electric pulse permeabilizes the cell membrane and electrophoresis transports the DNA directly to the nucleus, whereas others state that the DNA forms aggregates in the electropermeable regions of the plasma membrane and then moves to the nucleus via a biologically active process. In the BEP results described in this example, 20% of the transfected cells express GFP within the first hour and 80% express over the next 20 hours. This may indicate that both of the aforementioned mechanisms occur with BEP. A small proportion of cells expressing GFP immediately after treatment are able to electrophorese DNA directly into the nucleus, whereas the majority of cells expressing GFP after 4 hours require DNA to be transported to the nucleus, as with lipofection, for expression.

[0190] The DFE delivery paradigm combines membrane disruption and field effects to achieve higher efficacy, e.g., synergistic effects, compared to any of the individual techniques. Electroporation is amenable to DNA transfection of many cell types, but has limitations and can be toxic in the delivery of some materials, such as proteins. Mechanical disruption techniques, such as squeezing, have shown great success in delivering various materials, including proteins and nanomaterials, to a variety of cell types with minimal toxicity. However, these successes have been limited with DNA, due to presumed ineffective nuclear delivery. By combining mechanical disruption with electric field effects, DFE shows better, e.g., synergistic results on DNA expression, enabling the delivery of proteins, a milestone that is difficult to achieve with any of the individual methods mentioned above.

[0191] 1. Apparatus Fabrication and Experimental Setup A silicon wafer was bonded to a Pyrex wafer to form the DFE microfluidic device. Two major steps were involved in the fabrication: (1) fabrication of microfluidic channels on the silicon wafer, and (2) fabrication of microfluidic electrodes on the Pyrex wafer. The device was mounted on a holder with inlet and outlet reservoirs. An electric pulse was generated from an oscillator (Agilent E4422B), amplified through an amplifier, and drove the device through wires bonded to the electrode pads using conductive epoxy. A solution of cells mixed with the desired delivery substance (cargo compound or composition) is placed in the inlet reservoir. This reservoir is then connected to a compressed air line controlled by a regulator. Pressure (0-20 psi) is used to transport the fluid through the device and to apply an electric pulse to the device as the cells pass through. The cells are collected from the outlet reservoir for further processing.

[0192] As mentioned above, two major steps were involved in the fabrication of the microfluidic device, namely (1) the fabrication of electrodes on the Pyrex wafer and (2) the fabrication of microfluidic channels on the silicon wafer (Figure 13). Figure 13(a-d) shows the process of the electrodes. A photoresist layer (SPR3012, MicroChem, Newton, MA) was spin-coated on a 6-inch Pyrex wafer, patterned using a UV light source, and developed in a photoresist developer (MF CD-26, Microposit). A bilayer metal (Ti / Pt, 50 Å / 500 Å) was subsequently evaporated onto the wafer using an electron beam evaporator (Semicore Corp), and then the photoresist was removed by a lift-off process to form the electrodes and pads. As shown in Figure 13(e-h), the fabrication of the silicon microfluidic channel involved two steps of photolithography. A silicon wafer was first patterned with photoresist (Shipley 1827, MicroChem, Newton, MA) and etched by deep reactive ion etching (DRIE, Adixen, Hingham, MA). A second photolithography and DRIE were applied to etch the silicon wafer to form the inlets and outlets of the microfluidic device.

[0193] Finally, the silicon layer was sealed with a Pyrex layer using anodic bonding at 300 and 800 V. 6×23mm 2 The final device is shown in Figure 9B. The electrode finger width and gap space of the device used in the setup are 40 μm and 60 μm, respectively. The height of the microfluidic channel in the silicon substrate is 20 μm.

[0194] Cell culture: HeLa cells were cultured in 75T flasks containing 20 mL of DMEM medium supplemented with 10% fetal bovine serum (FBS, Invitrogen 16000). Cells were seeded in T flasks at 37 C in a humidified atmosphere containing 5% CO2.

[0195] Delivery materials: Fluorescently labeled molecules including dextran and plasmid DNA were mixed into the cell solution at a concentration of 0.1 mg / mL. DNA transfection was measured using GFP DNA plasmid.

[0196] Lipofection: The lipofection technique was demonstrated using the Lipofectamine 2000 DNA transfection kit. DNA-lipid complexes were prepared by combining 2 μL of Lipofectamine 2000 reagent with 100 μL of Opti-MEM medium containing 1 μg of DNA plasmid.

[0197] Microinjection: Microinjection of DNA plasmids into HeL cells was performed by trained technical staff at Massachusetts Institute of Technology. Thirty cells were injected each time. DNA concentration in injection buffer.

[0198] Other embodiments The subject matter described herein may be embodied in systems, devices, methods, and / or articles, depending on the desired configuration. The implementations described above do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the subject matter described. Although some variations have been described in detail above, other modifications or additions are possible. In particular, further features and / or variations may be provided in addition to those described herein. For example, the above implementations may be directed to various combinations and subcombinations of the disclosed features and / or combinations and subcombinations of some further features described above. Furthermore, the logic flow illustrated in the accompanying drawings and / or described herein does not necessarily require the particular order shown or sequential order to achieve the desired results. Other implementations may be within the scope of the appended claims.

[0199] The patents and scientific literature referenced herein establish knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are incorporated by reference. Genbank and NCBI submissions referenced herein by accession number are incorporated by reference. Other published documents, documents, manuscripts and scientific literature cited herein are incorporated by reference.

Claims

1. 1. A method for delivering an expression vector encoding a transgene into the nucleus of a cell, comprising: passing a cell suspension containing the cells and the expression vector through a cell deformation constriction, thereby exerting pressure on the cells and causing a perturbation of the cell membrane large enough to allow the expression vector to pass; and then passing the cell suspension through an electric field generated by at least one electrode to transport the expression vector into the nuclei of the cells; Including, The delivery method, wherein maximum expression of the introduced gene in the nucleus of the cell is achieved earlier than the corresponding maximum expression in the nucleus of a cell that has passed through the electric field without passing through the cell deformation constriction, or in the nucleus of a cell that has passed through the cell deformation constriction without passing through the electric field.

2. 2. The delivery method of claim 1, wherein maximum expression of the transgene in the nucleus of the cell is achieved about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 hours, or 0.1 to 4 hours earlier than the corresponding maximum expression in the nucleus of a cell that has been passed through an electric field without passing through a cell deformation constriction, or in the nucleus of a cell that has been passed through a cell deformation constriction without passing through an electric field.

3. 1. A method for delivering an expression vector encoding a transgene into the nucleus of a cell, comprising: passing a cell suspension containing the cells and the expression vector through a cell deformation constriction, thereby exerting pressure on the cells and causing a perturbation of the cell membrane large enough to allow the expression vector to pass; and then passing the cell suspension through an electric field generated by at least one electrode to transport the expression vector into the nuclei of the cells; Including, The delivery method, wherein the expression level of the introduced gene in the nucleus of the cell is higher than the corresponding expression level in the nucleus of a cell that has passed through the electric field without passing through the cell deformation constriction, or in the nucleus of a cell that has passed through the cell deformation constriction without passing through the electric field.

4. 4. The method of claim 3, wherein the expression level of the transgene in the nucleus of the cell is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% higher, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more higher than the corresponding expression level in the nucleus of a cell that has been passed through an electric field without passing through a cell deformation constriction, or in the nucleus of a cell that has been passed through a cell deformation constriction without passing through an electric field.

5. 4. The method of claim 3, wherein the level of expression of the transgene in the nucleus of a cell within about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours after the cell has passed through a cell deformation constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% higher, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more higher than the corresponding expression level in the nucleus of a cell that has passed through an electric field without passing through a cell deformation constriction, or in the nucleus of a cell that has passed through a cell deformation constriction without passing through an electric field.

6. 1. A method for delivering an expression vector encoding a transgene into the nucleus of a cell population, comprising: passing a cell suspension containing the cells and the expression vector through a cell deformation constriction, thereby exerting pressure on the cells and causing a perturbation of the cells large enough to allow the expression vector to pass through; and then passing the cell suspension through an electric field generated by at least one electrode to transport the expression vector into the nuclei of the cells; Including, The delivery method, wherein the percentage of cells in the nuclei of the cell population that express the introduced gene is greater than the percentage of corresponding cells in the nuclei of a cell population that passed through the electric field without passing through the cell deformation constriction, or the percentage of corresponding cells in the nuclei of a cell population that passed through the cell deformation constriction without passing through the electric field.

7. 7. The method of claim 6, wherein the percentage of cells in the nuclei of the cell population that express the transgene is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of cells in the nuclei of the cell population that passed through the electric field without passing through a cell deformation constriction, or the percentage of cells in the corresponding nuclei of the cell population that passed through the cell deformation constriction without passing through an electric field.

8. 8. The method of claim 6 or 7, wherein the percentage of cells expressing the transgene in the nuclei of the cell population within about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours after the cells have passed through the cell deformation constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of corresponding cells in the nuclei of the cell population that passed through the electric field without passing through the cell deformation constriction, or the percentage of corresponding cells in the nuclei of the cell population that passed through the cell deformation constriction without passing through an electric field.

9. 1. A method for delivering an expression vector encoding a transgene into the nucleus of a cell population, comprising: passing a cell suspension containing the cells and the expression vector through a cell deformation constriction, thereby exerting pressure on the cells and causing a perturbation of the cells large enough to allow the expression vector to pass through; and then passing the cell suspension through an electric field generated by at least one electrode to transport the expression vector into the nuclei of the cells; Including, The delivery method, wherein the proportion of cells in the nuclei of the cell population that express the introduced gene at high levels is greater than the proportion of corresponding cells in the nuclei of a cell population that passed through the electric field without passing through the cell deformation constriction, or the proportion of corresponding cells in the nuclei of a cell population that passed through the cell deformation constriction without passing through the electric field.

10. 10. The method of claim 9, wherein the percentage of cells in the nuclei of the cell population that express high levels of the transgene is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of corresponding cells in the nuclei of a cell population that passed through an electric field without passing through a cell deformation constriction, or in the nuclei of a cell population that passed through a cell deformation constriction without passing through an electric field.

11. 11. The method of claim 9 or 10, wherein the percentage of cells in the nuclei of the cell population that express high levels of the transgene within about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours after the cells have passed through the cell deformation constriction is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% greater, or 2-fold, 5-fold, 8-fold, 10-fold, 20-fold or more greater, than the percentage of corresponding cells in the nuclei of the cell population that passed through the electric field without passing through the cell deformation constriction, or the percentage of corresponding cells in the nuclei of the cell population that passed through the cell deformation constriction without passing through an electric field.

12. 1. A method for delivering an expression vector encoding a transgene into the nucleus of a cell, comprising: passing a cell suspension containing the cells and the expression vector through a cell deformation constriction, thereby exerting pressure on the cells and causing a perturbation of the cell membrane large enough to allow the expression vector to pass; and then passing the cell suspension through an electric field generated by at least one electrode to transport the expression vector into the nuclei of the cells; Including, The delivery method, wherein the introduced gene in the nucleus of the cell is expressed more quickly than the expression of the introduced gene in the nucleus of a cell that has passed through the electric field without passing through the cell deformation constriction, or in the nucleus of a cell that has passed through the cell deformation constriction without passing through the electric field.

13. 13. The method of claim 12, wherein expression of the transgene in the nucleus of the cell is achieved about 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 0.1 to 4 hours earlier than corresponding expression in the nucleus of a cell that has been passed through an electric field without passing through a cell deformation constriction, or in the nucleus of a cell that has been passed through a cell deformation constriction without passing through an electric field.

14. The method of any of claims 1 to 13, wherein the cell deformation constriction is in a microfluidic channel.

15. (a) passing cells through a microfluidic channel in a first device, then removing the cells from said first device and contacting them with an electric field in a second device; or (b) the microfluidic channel and the electric field are within one device; The delivery method of claim 14.

16. a microfluidic channel and an electric field are in one device, and cells enter the field in a continuous flow through a cell deformation constriction; (a) after passing through a cell deformation constriction, the cell contacts or passes through a portion of an electric field having sufficient strength to transport the payload via a transient perturbation; or (b) after passing through the cell deformation constriction, the cells enter and reside in a zone of the device where the cells come into contact with an electric field; The delivery method of claim 15.

17. 17. The method of any of claims 1 to 16, wherein the diameter of the cell deformation constriction is selected to induce a transient perturbation of the cell membrane large enough to allow a payload to pass, said diameter of the constriction being smaller than the diameter of the cell.

18. 18. The method of any of claims 1 to 17, wherein the diameter of the cell deforming constriction is about 20-99% of the diameter of the cell passing therethrough.

19. 19. The method of any of claims 1 to 18, wherein the diameter of the cell deforming constriction is about 4 μm, 5 μm, 6 μm, 7 μm, 8 μm, 9 μm, 10 μm, 15 μm, 20 μm, 4-10 μm, or 10-20 μm.

20. (a) the length of the cell deformation constriction is about 10 μm, 15 μm, 20 μm, 24 μm, 30 μm, 40 μm, 50 μm, 60 μm, 10-40 μm, 10-50 μm, or 10-60 μm; (b) the cell contacts the electric field within about 0.0001 seconds, 0.001 seconds, 0.002 seconds, 0.003 seconds, 0.004 seconds, 0.005 seconds, 1 second, 2 seconds, 3 seconds, 4 seconds, 5 seconds, 6 seconds, 7 seconds, 8 seconds, 9 seconds, 10 seconds, 0.001-0.005 seconds, or 0.0001-10 seconds after exiting the cell deformation constriction; (c) the exposure time of the cells to the electric field is about 10-50 ms, 50-100 ms, or 10-100 ms; (d) the electric field is a pulsed direct current; (e) pulsing the electric field; (f) the electric field strength or pulse strength is about 1-3 kV / cm, or 0.1-0.5 kV / cm, 0.1-1 kV / cm, 0.1-1.5 kV / cm, 0.1-2 kV / cm, 0.1-2.5 kV / cm, or 0.1-3 kV / cm; (g) the electric field strength or pulse strength is lower than that required to achieve the same level of delivery for a given payload to a particular cell type by electroporation alone; (h) the electric field strength or pulse strength is about 50%, 1-50%, 50-99%, or 1-99% lower than that required to electroporate the cells; (i) the cells are a plurality of cells and about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 90-95%, or 80-100% of the cells are viable after passing through the electric field; (j) pulsing the electric field with a duration of about 0.1 ms, with a period of 1-20 ms, 0.1-2000 ms, or 1-200 ms; (k) passing the cells through an electric field at a velocity of about 100 mm / s, 170 mm / s, 300 mm / s, 100-300 mm / s, 200-700 mm / s, 250-400 mm / s, 100-1000 mm / s, or 1-1000 mm / s; (l) the cell membrane perturbation has a maximum diameter of about 1-20 nm, 1-600 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 12 nm, 14 nm, 16 nm, 18 nm, 20 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, or 600 nm; and / or (m) a cell membrane perturbation having a maximum diameter of about 1-20 nm, 1-600 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 12 nm, 14 nm, 16 nm, 18 nm, 20 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, or 600 nm lasts for at least about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, or 1-10 minutes on the cell membrane; The delivery method according to any one of claims 1 to 19.

21. (a) forcing a cell suspension through a microfluidic channel using a pressure of about 10-100 psi; (b) passing the cells through the microfluidic channel at a velocity of about 300 mm / s, 100-300 mm / s, 200-700 mm / s, 250-400 mm / s, 100-1000 mm / s, or 1-1000 mm / s; and / or (c) the microfluidic channel has a single cell-deforming constriction, or the microfluidic channel has multiple cell-deforming constrictions in parallel and / or in series; The delivery method according to any one of claims 14 to 20.

Citation Information

Patent Citations

  • Intracellular Delivery

    US20140287509A1